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I. Introduction 
 
1. The family of cation-chloride cotransporters 
Cation-chloride cotransporters are integral membrane proteins encoded by the SLC12A 
genes. They transport cations such as Na
+
 and/or K
+
 together with Cl
- 
across the plasma 
membrane. There are nine members in this family: one sodium-chloride cotransporter 
(NCC), two sodium-potassium-chloride cotransporters (NKCC1-2), four potassium-
chloride cotransporters (KCC1-4), and two orphan members: CCC8 and CCC9 with no 
known functions (Table 1). The transport of these ions does not directly consume energy 
or change the electrical charge across the plasma membrane, therefore these transporters 
are called “secondary active electroneutral” cotransporters. The cation-chloride 
cotransporters take their energy from the Na
+
 or K
+
 gradient generated by the Na
+
/K
+
-
ATPase (Figure 1) (Price et al., 2009). In this family of proteins, members have different 
expression patterns in mammals, thereby they show a very wide range of physiological 
functions. Due to the ion gradient across the cell membrane, in most cases, NKCC and 
NCC cotransporters move Na
+
, K
+ 
and Cl
-
 into the cell, whereas  KCCs transport these 
ions out of the cells (Gagnon and Delpire, 2013). The major functions of these 
transporters are regulation of intracellular chloride concentration ([Cl
-
] i), trans-epithelial 
movement of ions, and cell volume regulation following osmotic challenges.   
A few human genetic diseases have been linked with mutations of genes in this family. 
For examples, mutations in NCC and NKCC2 lead to two syndromes called Gitleman’s 
syndrome  (NCC, (Simon and Lifton, 1996))  and Bartter's (NKCC2, (Simon et al., 1996)) 
syndromes. In Bartter syndrome, the deficit is located in the ascending thick limb of the 
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Figure 1. Cation-chloride cotransporters. 
 
 
NKCC transports Cl
-
 into the cell, whereas KCC transports Cl
-
 out of the cell. Both processes are 
electroneutral and take advantage of concentration gradients generated by the Na
+
/K
+
-ATPase 
(dotted arrows). 
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loop of Henle, whereas in Gitelman syndrome, the deficit happens in the distal 
convoluted tubule (Ng et al., 2006). The phenotypes of these two renal diseases include 
imbalance of ions resulting in hypokalemic metabolic alkalosis, hypomagnesaemia, and 
hypercalciuria (Roser et al., 2009).  In both syndromes, the impairment of NaCl 
reabsorption causes mild volume depletion, which leads to increases in renin and 
aldosterone release, resulting in K
+
 and H
+
 losses. Mouse models have been created with 
disruption of the genes encoding NCC and NKCC2 (Kemter et al., 2010; Schultheis et al., 
1998; Takahashi et al., 2000). These mice recapitulate the major symptoms of Gitleman 
and Bartter patients such as ion imbalance, metabolic acidosis and hypokalemia. Even 
though no human diseases resulting from NKCC1 mutations have been discovered, 
mouse models where NKCC1 is deleted have been established by several groups. The 
NKCC1 knockout mice have hearing loss, reproduction deficit, and impairment of 
salivation among other phenotypes (Delpire et al., 1999; Dixon et al., 1999; Flagella et al., 
1999). NKCC1 is expressed in certain epithelial cells of the mouse inner ear, and when it 
is deleted, we observe significant structural changes due to disrupted endolymph and 
endocochlear potential. NKCC1 is also expressed in spermatogonia (testis), sensory 
neurons (DRG), and many Cl
-
 secreting epithelia, explaining the multitude of phenotypes 
observed in the knockout mouse. 
For the four potassium chloride cotransporters, KCC2 is a neuron-specific member, 
found only in central neurons, i.e. brain and spinal cord. Currently, there are no human 
diseases related to KCC2 mutations, however, KCC2 has been shown to play a very 
important role during the development of mammalian neurons. KCC2 knockout mice 
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have been made but they die shortly after birth because of respiratory failure (Hubner et 
al., 2001).  
In the mammalian nervous system, KCC2 and NKCC1 is a pair of transporters which are 
important in modulating the activity of GABAergic (-amino butyric acid) neurons. In 
immature neurons (young animals), NKCC1 expression is high, leading to strong inward 
transport of chloride and high [Cl
-
]i. When GABA activates its receptor, the high [Cl
-
]i in 
the neuron facilitates the generation of a depolarizing current, which increases the chance 
of triggering an action potential. Upon neuronal maturation, the expression of NKCC1 
gradually decreases while KCC2 expression increases, strengthening or favoring the 
transport of Cl
-
 out of cell. Eventually the [Cl
-
]i is reduced to values that are lower than 
the electrochemical equilibrium potential of Cl
-
. In this situation, when GABA binds to 
its receptor, the current becomes hyperpolarizing and inhibitory, which is the normal 
condition for adult neurons (Ben-Ari et al., 2012; Lu et al., 1999; Plotkin et al., 1997) 
(Figure 2). 
In contrast, this “developmental switch” between NKCC1 and KCC2 does not occur in 
peripheral/dorsal root ganglion (DRG) neurons, where GABA-mediated current remains 
constantly depolarizing, due to sustained NKCC1 expression and absence of KCC2 
expression. The high NKCC1expression and activity leads to [Cl
−
]i  accumulation, 
leading to partial depolarization of the terminals of primary afferent neurons. This partial 
depolarization filters sensory noise and reduces the number of available Ca
2+
 channels 
upon activation, thus imposing an inhibitory effect (Rathmayer and Djokaj, 2000). This 
inhibitory input in primary afferents leads to a very important concept in neuroscience: 
presynaptic inhibition (Rudomin and Schmidt, 1999)(Figure 3). In a NKCC1 knockout 
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mouse model, severe locomotor deficit and nociception deficits were observed, revealing 
a key role for NKCC1in sensory perception.  
 
2. The K-Cl cotransporter-3, KCC3 
2.1. Discovery and Structure  
K-Cl cotransporters were first discovered from swelling- and N-ethylmaleimide (NEM)-
activated K
+
 efflux studies in sheep red blood cells (Dunham and Ellory, 1981; Lauf and 
Theg, 1980). Since then, four K-Cl cotransporters have been identified in a variety of 
tissues and cells: neurons, vascular smooth muscle, endothelium, heart (Adragna et al., 
2000; Amlal et al., 1994; Greger and Schlatter, 1983; Perry and O'Neill, 1993; Rivera et 
al., 1999; Weil-Maslansky et al., 1994; Yan et al., 1996). KCC1 and KCC2 were first 
identified in 1996 (Gillen et al., 1996; Payne et al., 1996), followed three years later with 
the identification of  KCC3 and KCC4 (Hiki et al., 1999; Mount et al., 1999; Race et al., 
1999). 
The structure of four KCC proteins is very similar with 12 transmembrane domains (TM) 
and a large extracellular loop located between TM5 and TM6 (Figure 4) (Gamba, 2005). 
KCC3 has a variety of potential phosphorylation sites, which make it a natural target of 
kinases for regulation (Gagnon and Delpire, 2012). Human KCC2 and KCC3, for 
instance possess the Arg-Phe-Xaa-Val (RFXV) amino acid sequences, which are binding 
sites for STE20/SPS1-related proline/alanine-rich kinase (SPAK) and oxidative stress 
responsive kinase 1 (OSR1) kinases.   
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Figure 2. Diagram showing NKCC1, KCC2 and the switch of the Cl
-
 movement in neuron 
development.  
 
 
A, In immature neurons, NKCC1 expression is high and GABAergic current is depolarizing and 
excitatory. B, In mature neurons, KCC2 expression is high and GABAergic current is 
hyperpolarizing and inhibitory.  
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Figure 3. NKCC1 cotransporter in dorsal root ganglion neurons. (Figure from Delpire lab). 
 
 
 (A) Sensory inputs from peripheral receptors are sent to the spinal cord through primary afferent 
fibers. (B) Sensory information is processed through dorsal root ganglion neurons where NKCC1 
is expressed abundantly. (C) Due to the high activity of NKCC1, intracellular chloride 
concentration is high and induces depolarizing GABAergic currents. (D) Sensory information is 
transmitted to neurons in the spinal cord for further processing. (E) Interneurons send inhibitory 
input into primary afferent terminals, releasing GABA neurotransmitters and causing presynaptic 
inhibition.  
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Our laboratory showed that SPAK and OSR1 are two kinases directly regulating KCC 
activity (Piechotta et al., 2002). There are several reports showing that WNK kinases and 
SPAK and OSR1 kinases in heterologous systems inhibit K-Cl cotransport, whereas 
another study failed to observe an inhibitory effect of SPAK on KCC through 
overexpressing the kinase(de Los Heros et al., 2006; Garzon-Muvdi et al., 2007; Kahle et 
al., 2005; Kahle et al., 2006).  These discrepancies reveal the complexity of the 
phosphorylation studies for this family of transporters. 
 
2.2  Spatial KCC3 Expression  
Through detailed studies, the expression of KCC3 transcript has been confirmed in a 
wide variety of organs and tissues: muscle, brain, spinal cord, kidney, and placenta (Hiki 
et al., 1999; Mount et al., 1999). Because of the presence of two alternative promoters, 
there are two KCC3 transcripts. The longer transcript expressing exon1a is called KCC3a 
and the shorter transcript is KCC3b (exon1b) (Pearson et al., 2001). Exon 2, which is a 
cassette exon, produces isoforms that contain or miss a 15 amino acid peptide (Mercado 
et al., 2005). KCC3a has a stronger presence in the brain whereas KCC3b is more 
abundant in the kidney. KCC3a is found in many regions of the nervous systems such as 
hypothalamus, cerebellum, brain stem, cerebral cortex and choroid plexus. While neurons 
mostly express KCC3a, there are a few non-neuronal cells such as radial glial-like cells 
that also express KCC3a (Shekarabi et al., 2011). A human disease called Andermann 
syndrome has been linked to mutations in KCC3 and this will be discussed later. 
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2.3. KCC3 function and activity 
Since its discovery in 1999, KCC3 has been studied in a variety of tissues, and the 
cotransporter mediates different functions, depending on its location. One of the best 
characterized roles of KCC cotransport is cell volume regulation, the process by which a 
cell is able to restore its normal volume following an osmotic challenge (Waldegger et al., 
1998). In a KCC3 knockout mouse model created by a German Group, renal cells and 
hippocampal neurons displayed deficit on cell volume regulation (Boettger et al., 2003). 
By taking advantage of this KCC3–/– mouse model, Rust and coworkers created a double 
knockout mouse in which both KCC1 and KCC3 were deleted (Rust et al., 2007). While 
the KCC1
–/–
 mouse did not show any transport deficit in red blood cells and KCC3
–/–
 
mice exhibited decreased K-Cl cotransport activity, in the double knockout mouse, the K-
Cl cotransport activity was almost completely abolished, suggesting a bigger role of 
KCC3 in these cells (Rust et al., 2007).This KCC3 knockout mouse displayed 
progressive hearing loss, which was also observed in KCC4 knockout mice as well. 
Detailed analysis showed that KCC3 was expressed in several key cell populations of the 
inner ear, including supporting cells of the hair cells and the organ of Corti epithelial cells. 
Loss of KCC3 leads to disrupted K
+
 transport and ion balance in the cochlea, which 
would eventually cause degeneration of sensory hair cells and ultimately deafness.  
Another phenotype exhibited by KCC3
−/−
 mice is an increased arterial blood pressure. 
Since chloride concentrations affects contraction activity of smooth muscle cells and 
thereby influence arterial blood pressure, it was tempting to assume that KCC3 might 
play a key role in vascular muscle tone activity. However, further analysis showed that 
this hypertension phenotype was actually due to increased activity of the sympathetic 
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Table 1. The SLC12 family of cation-coupled Cl
-
 cotransporters 
Member Co-transport ions Tissue distribution Disease 
SLC12A1 (NKCC2)  Na
+
-K
+
-2Cl
-
  Kidney-specific 
(TAL)  
Bartter's syndrome 
type I 
SLC12A2 (NKCC1)  Na
+
-K
+
-2Cl
-
  Ubiquitous  None 
SLC12A3 (NCC)  Na
+
-Cl
-
  Kidney-specific 
(DCT); bone?  
Gitelman's syndrome 
SLC12A4 (KCC1)  K
+
-Cl
-
  Ubiquitous  None 
SLC12A5 (KCC2)  K
+
-Cl
-
  Neuron-specific  None 
SLC12A6 (KCC3)  K
+
-Cl
-
  Widespread  Anderman's syndrome 
SLC12A7 (KCC4)  K
+
-Cl
-
  Widespread  None 
SLC12A8 (CCC9)  Unknown  Widespread  Psoriasis 
SLC12A9 (CIP)  Unknown  Widespread  None  
The SLC12 family consists of nine members. The transported ions, tissue distribution in 
mammals, and corresponding disease due to genetic mutations in humans are shown. 
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Figure 4. Structural topology for KCC cotransporters. 
For KCC proteins, there are 12 transmembrane domains, a large extracellular loop between the 
fifth and sixth transmembrane domain and a long carboxyl end. 
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nervous system (Rust et al., 2006).  More importantly, mice lacking the KCC3 
cotransporter also display severe locomotor deficit and progressive sensorimotor 
neuropathy in both peripheral and central nervous systems, which is addressed in the next 
section (Boettger et al., 2003; Byun and Delpire, 2007; Howard et al., 2002). 
 
3. Peripheral Neuropathy Disorders 
Peripheral neuropathy is the occurrence of a neuropathy in the peripheral nerves, which 
include motor, sensory, and autonomic nerves transmitting information between the 
central nervous system and peripheral organs (Hughes, 2002). It is a very common 
symptom with a fairly high prevalence rate. Indeed, it is estimated to affect about 2.4% of 
the US population, and this incidence rate increases to 8% for people older than 55 years.  
A recent study estimated the patient population suffering from peripheral neuropathy in 
the US to be around 20 million.  
Because of the wide range of peripheral nerves, the clinical symptoms of peripheral 
neuropathy vary widely (England and Asbury, 2004). Generally there are three major 
types of symptoms: sensory symptoms, weakness symptoms (motor) and autonomic 
symptoms. The diagnosis of this disorder requires detailed research on the patient’s 
history, clinical examination, electromyogram (EEM) studies, blood testing, glucose 
levels, nerve conduction studies, and lumbar puncture (Huan, 2010). Based on the 
number and distribution of nerves affected, or the process affecting the nerves, peripheral 
neuropathy can be further classified into different subtypes for treatment.  The most 
common neuropathy is the diabetic sensorimotor polyneuropathy, which appears in more 
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than half of the total diabetic population. Since the diabetes prevalence has been 
increasing all the time, it is estimated that diabetic neuropathy may affect 1% of the total 
US population currently (Van Acker et al., 2009). Another common neuropathy is 
idiopathic neuropathy, meaning that the cause of this neuropathy is unknown (Hughes, 
1995). In other parts of the world such as Southeast Asia, India, Africa, the highly 
prevalent leprous neuritis disease is still the leading cause of neuropathy (Martyn and 
Hughes, 1997). Beside these causes mentioned above, other factors such as infectious 
agents, vasculitis and toxins can also induce peripheral neuropathy. The treatment of 
neuropathy depends on accurate diagnosis of specific peripheral nerves affected. 
Glycemic control is very important for diabetic neuropathy, while a few immune-based 
modulating methods are available for idiopathic neuropathy. Right now there are no 
effective and potent strategy to completely cure this disorder, most of the current 
treatment methods focus on improvement of patient conditions (Torpy et al., 2010).  
 
4. HMSN/ACC  
4.1. Disease overview 
Peripheral neuropathy associated with agenesis of the corpus callosum (ACCPN, OMIM#: 
218000), also known as hereditary motor and sensory neuropathy associated with 
agenesis of the corpus callosum (HMSN/ACC), or Andermann syndrome, is a hereditary 
autosomal recessive human disease (Dupre et al., 2003). This disease was first described 
in 1966 by Leblanc and colleagues and then subsequently characterized by Andermann 
and colleagues in 1970s (Andermann et al., 1975; Andermann et al., 1972).  One of the 
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hallmarks of this disorder is the agenesis of the corpus callosum, which is a thick band of 
nerve fibers connecting the left and right hemisphere. Corpus callosum is very important 
for communication between the two cerebral hemispheres and the agenesis and 
degeneration lead to multiple neurological symptoms for both motor and sensory 
functions. It was found that not all ACCPN patients have this symptom in postmortem 
examination, and the degree of agenesis also varied among patients. Other common 
symptoms include abnormal or absent reflexes, intellectual disability, weak muscle tone, 
and dysmorphism of different organs. Most patients can live until adulthood, but usually 
they will die by their third decade, although the care of patients is improving and 
extending life (Dupre et al., 2003). 
This is a very rare hereditary human disease with only a few sporadic reports available 
from most parts of the world. However, ACCPN has a very high prevalence in two 
regions of Quebec, Canada: the Saguenay-Lac-St-Jean region and in Charlevoix County. 
In the local French Canadian population, the overall incidence rate of ACCPN is 1 in 
2,117 live births and the carrier rate is 1 in 23. The genetic mutations of ACCPN in this 
area was traced back to a set of 22 French individuals from Poitou, Perche, and other 
regions who migrated to Canada in the 17
th
 century (De Braekeleer et al., 1993). 
Therefore, this founder effect is the major reason for such a high disease prevalence in 
this region of Canada.  
Since its first description, extensive studies have been performed to uncover the cause of 
the disease. In 1996, a genome wide analysis in Quebec French Canadian population was 
performed using microsatellite DNA markers (Casaubon et al., 1996). The authors were 
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able to map the ACCPN gene to a region on the long arm of chromosome 15, thus 
making a significant step towards the identification of the ACCPN gene. It was the 
cloning of KCC3 at Vanderbilt University (Mount et al., 1999), the mapping of the gene 
to the same region of chromosome 15, the foresight of the possible connection, and the 
collaborative work of the Vanderbilt and McGill groups that led to the identification of 
the KCC3 gene as the gene involved in HMSN/ACC (Howard et al., 2002) .  
Ten different KCC3 mutations have been found in ACCPN patients around the world. 
Among them the most common one is the mutation found in the French Canadian 
population in Quebec, Canada. It is a guanine deletion in exon 18 of the SLC12A6 gene 
(c.2436delG, Thr813fsX813), resulting in a frame shift mutation and truncated KCC3 
protein (Howard et al., 2002). Another frame shift mutation was found in exon 15 
(c.2023C-T, Arg675X) in an Italy case, resulting a truncated KCC3 protein as well. In 
fact most of the known ACCPN mutations lead to a truncated KCC3 protein where the C-
terminus is absent, suggesting a possible role of the C-terminus of KCC3 in the 
development of ACCPN.  
 
4.2. Animal models 
In 2001-2002, our laboratory generated the first animal model for ACCPN by deleting 
exon 3 from the mouse Slc12a6 gene by homologous recombination (Howard et al., 
2002). Exon 3 (95 bp) encodes a small portion (31 amino acids) of the N-terminal of the 
cotransporter and its deletion not only eliminates this sequence, but places the remainder 
of the protein out-of-frame, so that no functional protein can be expressed. Initial 
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observations failed to show an overt phenotype, except a low posture. However, closer 
observations revealed the presence of a significant locomotor deficit in these knockout 
mice. Three tests were used to assess the locomotor deficit: a rotorod test, a wire-hang 
test and a beam-task test. Compared with the control or heterozygotes, the homozygote 
knock outs failed all three tests, suggesting a severe impairment of the normal locomotor 
function (Figure 5).  The pathology of the knockout mice was also examined. In the 
knockout, anatomical analysis showed severe neuron degeneration in the sciatic nerves, 
including myelin debris and thin myelin layers. Further analysis of the sciatic nerves of 
the mutant mice showed axonal and periaxonal swelling and axon and myelin 
degeneration (Byun and Delpire, 2007). These results explained the locomotor deficit 
phenotype and recapitulated the pathology seen in peripheral nerves of patients with 
ACCPN (Dupre et al., 2003).  
In 2003, a group in Germany created a separate mouse model of ACCPN by deleting the 
whole region after exon 1 of KCC3 (Boettger et al., 2003). In this independent study, the 
authors also observed severe motor function deficit and progressive neurodegeneration as 
seen in the previous mouse model. In addition, this new KCC3
-/-
 mice revealed some 
additional important phenotypes. Even though no seizure activity was observed in these 
mice, the seizure threshold in the knockout mice was reduced. The electrocorticograms of 
the mutant mice had a very similar pattern to those obtained from patients with 
Andermann syndrome. As mentioned above, arterial blood pressure of the mutant mice 
was significantly higher than that of control mice, likely due to an elevated sympathetic 
tone. The mutant mice also lost their hearing ability slowly, revealing a new role of 
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KCC3 in inner ear.  By revealing additional roles of KCC3, this study provided an 
invaluable mouse model for ACCPN disease.  
In order to further define the role of KCC3 in the pathogenic mechanisms leading to 
ACCPN, Guy Rouleau and colleagues recently created a neuron-specific KCC3-null 
mouse line (Shekarabi et al., 2012). The neuron-specific KCC3-null mice showed similar 
locomotor deficit as the straight KCC3-null mice, however, the auditory defects observed 
in ubiquitous KCC3-null mice were missing in the neuron-specific ones, consistent with 
intact function of KCC3 in non-neuronal cells in the cochlea. This novel model 
confirmed a key role of KCC3 in the nervous system and provided important insights 
about the origins of this disease.  
 
5. Creation of genetically-modified mouse models  
In current biomedical research, model organisms have become critical tools in helping 
scientists understand specific biological processes. The principle of biological 
universality, which infers that “rigorous and analytic study of the biology of any 
organism is likely to lead to findings of importance in the understanding of other 
organisms” , has been widely accepted among scientists (Horvitz, 2003). Model 
organisms include the bacterium Escherichia coli, bakers' yeast Saccharomyces 
cerevisiae, the nematode worm Caenorhabditis elegans, the fruit fly Drosophila 
melanogaster, and the mouse Mus musculus (Fields and Johnston, 2005). Every model  
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Figure 5. Slc12a6-mutated mice showed significant motor deficit. (Figure from Delpire lab). 
 
In three different motor function tests (a−c), significant deficits were observed in homozygous 
but not heterozygous mutant mice as compared to wildtype mice. 
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organism has a unique set of advantages and disadvantages which make it useful for a 
particular set of scientific problems. In the study of a complex human disease such as 
ACCPN, the mouse Mus musculus has emerged as a premier candidate for understanding 
the human disorder. The mouse shares 99% of its genes with human, and it has been used 
to study many important human disorders, such as hypertension, diabetes, cancer, heart 
disease and neurological illnesses. Compared to larger mammals such as dogs or primates, 
the mouse is advantageous due to its small size, relatively shorter gestation period, and 
cost of maintenance (Peters et al., 2007). In 2007, a trio of scientists (Drs. Mario R. 
Capecchi, Martin J. Evans, and Oliver Smithies) was awarded the Nobel Prize in 
Physiology/Medicine for their innovative work in producing genetically modified mice 
with the embryonic stem (ES) cells and homologous recombination technology.  
With the gene targeting technology, scientists are able to introduce foreign genes into the 
mouse genome to create transgenic mice, or modify existing genes by homologous 
recombination in embryonic stem cells, thus generating knockout or knock-in mice 
(Figure 6). A knockout mouse is genetically engineered to inactivate a gene or "knock 
out" its product. This can be achieved by either introducing a piece of DNA or removing 
an exon with the goal of disrupting the transcript (Anagnostopoulos et al., 2001). The 
deletion of the gene will mostly induce relevant phenotypes associated with the normal 
function of the corresponding gene, including behavior and other physical and 
biochemical features. In contrast, a mouse “knock-in” takes advantage of the native 
promoter to either drive expression of the protein which has been changed with the 
addition of an epitope tag or with a mutation. The knock-in strategy can also be used to 
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drive the expression of another protein. A knock-in mouse can result in a phenotype 
similar to that of a knockout if the mutation also leads to a non-functional protein. 
Knockout mice with a specifically targeted gene are often used as animal models of 
hereditary human diseases (Friedel et al., 2011). However, in many cases the gene 
deleted is very essential therefore the knockout mouse is embryonic lethal. An alternative 
strategy to go around the lethality is to deactivate the gene in certain and specific 
conditions by taking advantage of the Cre-loxP system where a Cre mouse line and a 
loxP mouse line are both required (Garcia-Otin and Guillou, 2006). For the loxP mouse 
line, a targeted gene is modified by inserting two loxP sites flanking the exon, therefore 
allowing the exon to be targeted and excised by Cre-mediated recombination. This is 
achieved by mating the mice containing the modified loxP gene with mice carrying the 
Cre recombinase under a specific promoter. This strategy will lead to gene knockout in a 
specific spatial or temporal manner. Indeed, there are two main subtypes of conditional 
knockouts: tissue specific knockouts where protein is deleted in a specific tissue or cell 
type, and an inducible knockout where protein disruption can be induced through diet 
manipulation or chemical reagents. In order to obtain expression of an altered protein, a knock-in 
mutation can be introduced into the mouse genome, using the same technology for knock-outs 
(Roebroek et al., 2011). For instance, rather than deleting an exon, the wild-type exon can be 
replaced with a mutated exon with altered protein product. The exon may also need to be flanked 
by loxP sites to allow for homologous recombination.  
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Figure 6. General procedures for creating transgenic mice.  
 
Embryonic stem (ES) cells or inner mass cells were isolated from a mouse blastocyst and DNA 
construct is inserted into the cell through electroporation. After homologous recombination, 
positive ES cell clones are injected into C57BL/6J blastocysts which are implanted into 
pseudopregnant females. The newborn mice are chimeric animals created from both donor 
(blastocyst) and recipient (mutated ES) cells. If these chimeric animals transfer the mutation to 
the next generation, the progeny will carry the mutated gene. 
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Hypothesis and Specific Aims 
 
Hypothesis I: 
While it is clear that KCC3 is responsible for HSN/ACC (ACCPN), the precise 
mechanism by which the cotransporter causes the disorder is unknown. The first 
symptoms of ACCPN are observed in early childhood and worsen with age. The first 
posture and locomotion deficits are also observed early in the KCC3 knockout mouse,  
and also worsen with age. Whether the disorder has developmental and/or degenerative 
components is still unknown. In fact, it is not even known if absence of the K-Cl 
cotransport function of KCC3 is required to produce the disorder. Indeed, since all (but 
one) ACCPN-causing mutations in KCC3 result in either absence of protein or in 
truncated proteins, and the knockout models also generate absence of KCC3, it is 
possible that absence of the protein or a specific protein domain, rather than the absence 
of the K-Cl cotransport function of KCC3, is responsible for the disorder. 
  During the cloning of the mouse KCC3 by RT-PCR, the laboratory created a cDNA 
which when transcribed failed to demonstrate K
+
 transport in Xenopus laevis oocytes. 
The cDNA was re-sequenced and an adenine to guanine substitution at nucleotide 
position 866, leading to mutation of glutamic acid residue 289 into a glycine (E289G), 
was identified. As this mutation is located in an extracellular loop between two 
transmembrane domains, the mutation is unlikely to affect the structure of the 
cotransporter. Therefore, I hypothesize that an E289G knock-in mutation resulting in 
absence of K-Cl cotransport function in the mouse will tell us if the absence of K-Cl 
cotransport function is required for the development of the neuropathy.  
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Specific Aim I: To characterize the absence of KCC3-E289G function in vitro. This will 
be achieved by studying KCC3-E289G in Xenopus laevis oocytes and in HEK293 cells. 
Expression and trafficking of the KCC3-E289G protein will be examined in both 
heterologous expression systems.  
Specific Aim II: To create and characterize the phenotype of a KCC3-E289G knock-in 
mouse. This will be achieved by knocking-in mutated exon 7 by homologous 
recombination, obtaining viable homozygous animals and studying its locomotor 
phenotype. 
 
Hypothesis II: 
In humans, morphological abnormalities are found in both grey and white matter, 
suggesting that the ACCPN disorder affects both neurons and supporting cells. In the 
mouse of KCC3 null mice, although the agenesis of the corpus callosum (white matter 
tracts dividing the two brain hemispheres) is not observed, vacuoles are observed in brain, 
spinal cord, and nerves, suggesting pathology of supporting cells. Nerves in particular 
present deficits that seem to affect both neurons and Schwann cells. Thus, understanding 
the precise cellular origin of the disorder might help us design strategies to understand the 
role that the cotransporter plays in the disease. Thus, I hypothesize that a very specific 
population of neurons is responsible for the development of ACCPN. 
Specific Aim I: To create a novel KCC3flox mouse and several tissue-specific KCC3 
knockout to identify the cellular origin of the neuropathy. This will be achieved by 
targeting the KCC3 locus by homologous recombination and obtaining a viable KCC3 
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floxed line and crossing this line with several transgenic CRE lines, thus targeting 
neurons in general, proprioceptive neurons, nociceptive neurons, and Schwann cells. 
Specific Aim II: Characterize the locomotor phenotype of these tissue-specific KCC3 
knockout mice. This will be achieved by creating cohort of each tissue-specific knockout 
mouse and appropriate controls and assess locomotor activity through the use of 
accelerated rotorad test and distance traveled in open field. When appropriate, combine 
these studies with immunohistochemistry studies to further characterize these mice.  
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II. Characterization of KCC3 E289G mutant in vitro 
 
1. Introduction 
In mammals, electroneutral and Na
+
-independent K–Cl cotransport is mediated by 4 
distinct genes: SLC12A4-A7 (Gagnon and Delpire, 2013). The products of these genes 
(KCC1-KCC4) fulfill a variety of physiological roles which include cell volume 
maintenance and regulation (Hoffmann et al., 2009) , Cl
-
 homeostasis (Blaesse et al., 
2009; Delpire, 2000; Kahle et al., 2008; Lauf et al., 2006), epithelial transport (Lauf et al., 
2006), control of migration, proliferation, and invasiveness (Chen et al., 2010). K–Cl 
cotransporters are regulated by phosphatases (Jennings and Schulz, 1991) and the WNK-
SPAK/OSR1 phosphorylation cascade (Gagnon and Delpire, 2012; Kahle et al., 2010) . 
Mutations in SLC12A6, the gene which encodes for the K–Cl cotransporter-3 (KCC3), 
results in a rare autosomal recessive neurological disorder known as Hereditary Motor 
and Sensory Neuropathy/Agenesis of the Corpus Callosum (HSMN/ACC) (OMIM 
218000; (Boettger et al., 2003; Howard et al., 2002)). The pathological hallmarks of this 
syndrome, with high prevalence in the French-Canadian population of Quebec, are a 
peripheral neuropathy which is often associated with variable agenesis of the corpus 
callosum, areflexia, mental retardation, and psychosis (Filteau et al., 1991; Larbrisseau et 
al., 1984). KCC3-deficient mice exhibit not only the early onset and severe locomotor 
deficits similar to the crippling human peripheral neuropathy disorder (Howard et al., 
2002), but also high blood pressure, age-related deafness, and renal dysfunction (Boettger 
et al., 2003). At the ultrastructural level, KCC3-deficient mice exhibit axonal and peri-
axonal swelling indicating both neuronal and Schwann cell defects (Byun and Delpire, 
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2007). A recent study that used a synapsin 1-CRE mouse to drive deletion of neuronal 
KCC3 expression reproduced the neuropathy phenotype observed in the KCC3 knockout 
mouse (Shekarabi et al., 2012). 
Injection of KCC3-T813X, the prevalent mutation observed in the French-Canadian 
population, in Xenopus laevis oocytes demonstrated expression of a glycosylated protein 
of a smaller molecular size at or near the oocyte plasma membrane similar to wild-type 
KCC3. In contrast, a novel and more distal HMSN/ACC truncating mutant (KCC3-
R1134X) failed to traffic properly to the plasma membrane (Salin-Cantegrel et al., 2011). 
Several studies have reported expression of more than one K–Cl cotransporter isoform in 
cells and tissues, including red blood cells (Crable et al., 2005); glial cells (Gagnon et al., 
2007); vascular smooth muscle cells (Di Fulvio et al., 2001); and suprachiasmatic 
neurons (Belenky et al., 2010). In fact, most large CNS neurons such as cortical or 
hippocampal pyramidal cells express both KCC2 and KCC3 (Pearson et al., 2001), and 
disruption of either cotransporter elicits shifts in the GABA reversal potential (Boettger et 
al., 2003). The fact that cells express multiple KCC isoforms suggests the intriguing 
possibility that these cotransporters interact with one another, a view supported by an 
early evidence of isoform hetero-dimerization (Casula et al., 2001). 
In this study, we take advantage of a full-length KCC3-E289G mutant that maintains the 
entire open reading frame, but renders the cotransporter functionally inactive to assess 
interaction, trafficking, and function of co-expressed K-Cl cotransporters. While this 
mutation is not found in nature, it still provides important information on a specific 
residue of the K–Cl cotransporter and constitutes a very useful tool to study its trafficking 
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and hetero-oligomerization. We provide evidence that K–Cl cotransporter isoforms 
interact in Xenopus laevis oocytes and affect each other's function. We demonstrate that 
the mutant KCC3-E289G protein resides in the endoplasmic reticulum (ER), is not 
properly glycosylated, and does not traffic to the plasma membrane. Furthermore, we 
show that the E289G mutant also prevents wild-type KCC3 as well as another K–Cl 
cotransporter isoform to traffic to the plasma membrane. 
 
2. Methods 
Cloning of mouse KCC3 cDNA. The entire open reading frame of the mouse KCC3a 
was constructed by ligating into Bluescript (pBSK+) several PCR fragments obtained 
from David B. Mount (Vanderbilt University). The clone was sequenced and moved into 
the oocyte expression vector pBF. As the cDNA failed to demonstrate K
+
 transport, the 
cDNA was re-sequenced and an adenine to guanine substitution at nucleotide position 
866, leading to mutation of glutamic acid residue 289 into a glycine was identified. After 
the mutation was corrected using QuikChange mutagenesis, the clone was re-sequenced 
and re-tested for functionality. 
Isolation of Xenopus laevis oocytes. All procedures performed with frogs were approved 
by the Vanderbilt University Institutional Animal Care and Use Committee. Stages V and 
VI Xenopus laevis oocytes were isolated from 16 different frogs as previously described 
(Delpire et al., 2011) and were maintained at 16°C in modified L15 medium (Leibovitz’s 
L15 solution diluted with water to a final osmolarity of 195-200 mOsM, supplemented 
with 10 mM HEPES and 44 µg of gentamicin sulfate). The next day, oocytes were 
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injected with 50 nl of water containing 2-15 ng of cotransporter cRNA (concentrations 
are indicated in specific experiments) and oocytes are incubated for 3 days prior to use. 
K
+ 
uptakes in Xenopus laevis oocytes. Groups of 20-25 oocytes were washed once with 
3 ml isosmotic saline (96 mM NaCl, 4 mM KCl, 2 mM CaCl2 1 mM MgCl2, 5 mM 
HEPES buffered to pH 7.4, 200 mOsM) and pre-incubated for 15 min in 1 ml Na
+
 free 
isosmotic or hyposmotic saline containing 1 mM ouabain. The solution was then 
aspirated and replaced with 1 ml Na
+
 free isosmotic or hyposmotic flux solution 
containing 5 µCi 
86
Rb. Two 5 µl aliquots of flux solution were sampled at the beginning f 
each 
86
Rb uptake period and used as standards. After 1 h uptake at room temperature, the 
radioactive solution was aspirated and the oocytes were washed 4 times with 3 ml ice-
cold Na
+
 free isosmotic or hyposmotic solution. Single oocytes were transferred into 
glass vials, lysed for 1 h with 200 µl 0.25N NaOH, neutralized with 100 µl glacial acetic 
acid, and 
86
Rb
 tracer activity was measured by β-scintillation counting. KCC flux is 
expressed in nmoles K
+
/oocyte/h.  
Immunoprecipitation. Stage V-VI Xenopus laevis oocytes were microinjected with 15 
ng each mKCC3 and/or rKCC2 cRNAs and incubated for 3 days at 16
o
C.  Oocytes were 
then homogenized by passing them through a pipet tip (50 µl / oocyte) in 50 mM HEPES 
supplemented with Complete™ Protease Inhibitor Cocktail Tablet, EDTA-free (Roche). 
Homogenates were then centrifuged at 15,000 x g for 1 min and supernatants were saved 
for protein assay (Bradford, BioRad). An equal amount of protein was added to the 
HEPES buffer to a final volume of 1 ml. Immunoprecipitation was achieved by adding 10 
μl of anti-GFP (IgG negative control), anti-KCC3, or anti-KCC2 antibody to the 
homogenate sample under gentle rotation overnight at 4°C. Then, 30 μl of pre-washed 
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Protein A sepharose (Santa Cruz Biotechnology, Santa Cruz, CA) was added to each 
homogenate and incubated for 2 h at 4°C. The sepharose beads or expected 
immunoprecipitates were washed three times with 1 ml of lysis buffer (centrifugation at 
4 °C, 2000 rpm, 2 min). The immunoprecipitates were re-suspended in 75 μl of loading 
buffer that contained 8% β-mercaptoethanol, heated at 75°C for 15 min, and subjected to 
SDS-PAGE. 
Western Blot Analysis. Protein samples were denatured in SDS-PAGE loading buffer at 
75°C for 15 min and separated on a 6%, 7.5% or 9% SDS-polyacrylamide gels. The 
separated proteins were electroblotted onto polyvinylidine fluoride membranes through a 
semi-dry process, and membranes were incubated for 2 h at room temperature in blocking 
solution (5% nonfat milk in Tris-buffered saline with 0.5% Tween 20). Incubation of 
primary antibody was performed overnight at 4 °C. The dilutions used for the antibodies 
were: KCC3 1:250, KCC2 1:250, PDI-ER marker 1:1000, GAPDH-cytosol marker 
1:1000. Membranes were washed in TBST for 3 h, incubated with their corresponding 
horseradish peroxidase-conjugated secondary antibody in blocking solution (1:5000) for 
1 hour at RT, and washed again for 2 h in TBST. Protein bands were visualized by 
chemiluminescence (ECL Plus, Amersham Biosciences). 
Cell surface expression in Xenopus laevis oocytes. Isolation of plasma membrane 
bound proteins was done following (Leduc-Nadeau et al., 2007). Briefly, 3 days after 
microinjection of cRNA, 40-60 oocytes were rinsed three times in modified MBSS (80 
mM NaCl, 20 mM MOPS pH 6.0) and incubated for 10 min at room temperature with 
modified MBSS supplemented with 0.005% subtilisin A (Sigma, St. Louis, MO) under 
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gentle agitation to promote vitelline membrane digestion. Membrane polymerization was 
performed at 4
o
C under mild agitation by first incubating the oocytes with modified 
MBSS with 1% ludox colloidal silica (Sigma), and then with modified MBSS with 0.1% 
polyacrylic acid (Sigma). Between each incubation period, oocytes were rinsed three 
times in modified MBSS. The oocytes were then homogenized with 0.5 ml of cold HbA 
(5 mM MgCl2, 5 mM NaH2PO4, 1 mM EDTA, 80 mM sucrose, and 20 mM Tris pH 7.4). 
This homogenization was carried out manually by passing the oocytes through a 200 ul 
pipette tip. The homogenates were washed with 1.5 ml with HbA and centrifuged at 16 g 
for 30 sec at 4°C. The pellets were resuspended and subjected to a series of 
centrifugations: 16 g, 25 g and 35 g for 30 sec and max speed for 20 min. The pellets of 
purified plasma membranes were resuspended in 45 µl of HbA and frozen until use. 
Cell culture and Transfection.  HEK 293FT (Invitrogen, Carlsbad, CA) cells were 
maintained and routinely passaged in DMEM-F12 supplemented with 10% fetal bovine 
serum and 1% Penicillin/Streptomycin (Invitrogen) at 37°C under 95% air, 5% CO2. For 
transfection, cells were trypsinized and plated at 30% density the day prior to transfection. 
The cDNAs were then transfected into the cells using FuGENE 6 (Roche Applied 
Science) at a 3:1 ratio (DNA:transfection reagent). Transfected cells were incubated at 
37°C under 95% air, 5% CO2 for 48 h prior to use. 
HEK 293FT sub-cellular fractionation. The method was adapted from (Holden and 
Horton, 2009). HEK 293FT cells grown in 10-cm dishes were transfected with 16 ug of 
KCC3-pIRES _puro2 or KCC2-pIRES_puro2 and 48 h later, the culture medium was 
removed and cells were detached with 500 µL of Trypsin-EDTA (0.05%, Invitrogen). 
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Cells were resuspended in 10 ml of complete culture medium, centrifuged at 100 x g at 
4
o
C for 2 min. Next, the supernantant was aspirated and the cells were washed by gentle 
pipetting in 10 ml of Hank's Balanced Salt Solution. Cell suspension was centrifuged 
again at 100 x g at RT to pellet the cells. Supernatant was removed and the cell pellet was 
resuspended by gently adding 1 ml of ice cold buffer 1 (25 µg/ml digitonin, 150 mM 
NaCl, 40 mM HEPES pH 7.4) containing protease inhibitors (1 tablet of complete 
protease inhibitor cocktail per 10 ml). Cell suspension was gently rotated at 4
o
C for 5 min. 
The sample was then centrifuged at 2000 x g. Supernatant which constitutes the cytosol - 
membrane enriched fraction was recovered and saved. The pellet was resuspended by 
vortexing in 1 ml of ice-cold buffer 2 (1% NP40, 150 mM NaCl, 40 mM HEPES pH 7.4). 
Samples were incubated on ice for 30 min and then centrifuged at 7000 x g to pellet 
nuclei and cell debris. The supernatant which comprises membrane bound organelles 
such as the ER, Golgi, mitochondria and some nuclear lumenal proteins was recovered 
and saved. Finally, the pellet was resuspended by vortexing in 1 ml of ice cold buffer 3 
(0.5% Na-deoxycholate, 0.1% SDS, 1U/ml benzonase, 150 mM NaCl, 40 mM HEPES 
pH7.4). Samples were rotated gently overnight at 4
o
C to allow complete solubilization of 
nuclei and digestion of genomic DNA. The supernatant which comprises nuclear 
membranes and nuclear proteins was finally recovered. 
Immunofluorescence. HEK 293FT cells grown on glass coverslips and transfected with 
wild-type or mutant KCC3 were washed in PBS twice at room temperature and fixed 
with 2% paraformaldehyde in PBS for 30 minutes. The cells were then permeabilized by 
incubating them twice for 5 min with PBS containing 0.075 % saponin (Sigma, St Louis, 
MO). After blocking with PBS containing 0.075 % saponin and 0.2 % BSA for 30 
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minutes, the cells were incubated for 1 hour at RT with 150 µl primary antibodies: rabbit 
polyclonal anti-KCC3 antibody (1:250, (Byun and Delpire, 2007)) and mouse 
monoclonal anti-PDI antibody (Abcam, Ab27043 1:200), followed by 3 x 5 min washes 
with PBS/saponin/BSA and then incubated for 1 hour at RT with 150 µl secondary 
antibodies: Cy3 conjugated anti-rabbit antibody (1:1000, Jackson Immunochemicals)  
and Alexa Fluor anti-mouse IgG (H+L) (1:400, Invitrogen).  After final 3 x 5 min washes 
in PBS/saponin/BSA solution, coverslips were mounted on slides using VectaShield 
(Vector Laboratories, Burlingame, CA) and sealed with nail polish. Fluorescence signal 
was visualized using a Carl Zeiss LMS 510 META confocal microscope. 
 
3. Results  
During the process of cloning the mouse KCC3 cDNA, we came across a mutation 
resulting in the substitution of glutamic acid residue E289 into a glycine (E289G). This 
negatively charge residue, located at the end of trans-membrane domain 3 (TM3) or 
beginning of extracellular loop 2 (ECL2) is highly conserved in all mammalian cation-
chloride cotransporters (Figure 7A). Although the KCC3-E289G mutant was non-
functional when expressed in Xenopus laevis oocytes, function was restored when the 
residue was mutated back into a glutamic acid (Figure 7B).  
To demonstrate hetero-dimerization of K-Cl cotransporters, we chose to study the 
interaction between KCC3 and KCC2, a cotransporter that demonstrates activity under 
isosmotic conditions. In Figure 8, we co-expressed, wild-type KCC3, and KCC3-E289G 
in Xenopus laevis oocytes and used co-immunoprecipitation to show specific protein-
33 
 
protein interactions. First, we immunoprecipitated KCC3 proteins and immunoblotted for 
KCC2 (Figure 8, panel A: lanes 4 & 5) or inversely immunoprecipitated KCC2 and 
immunoblotted for KCC3 (Figure 8, panel B: lanes 2 & 3). No immunoprecipitation was 
observed with unrelated IgG, and neither antibody cross-reacted with the other K-Cl 
cotransporter (Figure 8, panel A: lane 6, panel B: lane 1). Lanes 1-3 of panel A constitute 
internal controls. Note the smaller molecular size of the KCC3-E289G band, indicating 
possible impairment in glycosylation. 
Next, we measured K-Cl transport activity through K
+
 influx measurements in Xenopus 
laevis oocytes (Figure 9A). Under isotonic conditions, KCC2-injected oocytes showed 
significant K
+
 influx compared to water-injected oocytes. Under isotonic conditions, 
KCC3-injected oocytes showed no activity, but the activity could be observed upon 
hyposmotic treatment. When co-injected with wild-type or E289G mutated KCC3, KCC2 
activity was significantly reduced compared to KCC2 alone under isotonic conditions. 
Because KCC3 is inactive under isosmotic conditions, we also examined the effect of 
KCC3 wild-type and KCC3-E289G on KCC2 under hypotonic conditions. Based on the 
activity of each cotransporter under hypotonic conditions, we anticipated an additive 
effect (showed by the arrowed vertical line). However, we again observed a flux that was 
smaller than KCC2 alone. To demonstrate that this was not due to cRNA saturation, we 
injected 6 ng KCC2 RNA and observed a significant increase in flux, compared to a 2 ng 
KCC2 injection. Importantly, we demonstrated that the inhibitory effect of KCC3-E289G 
on KCC2 function was specific to K-Cl cotransporters, by co-injecting mRNA encoding 
KCC3-E289G and NKCC1, and observing no inhibitory effect on NKCC1-mediated K
+
 
uptake (Figure 9B). This control experiment was important as it demonstrated that 
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Figure 7. Absence of function of the KCC3-E289G mutant protein. 
 
A) Conservation of glutamic acid residue (E289 in mouse KCC3) within mouse SLC12A 
cotransporters. The residue, highlighted by an arrowhead in cartoon and sequence alignment, is 
localized at the end or right downstream of transmembrane domain 3 (TM3). B) K
+
 influx was 
measured through unidirectional 
86
Rb tracer uptake under isosmotic and hyposmotic conditions, 
in oocytes injected with water, KCC3-E289G mutant cRNA, and wild-type KCC3 cRNA. Bars 
represent mean ± SEM (n = 25 oocytes). 
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Figure 8. Co-immunoprecipitation reveals interaction between KCC3 and KCC2. 
 
Xenopus laevis oocytes were injected with KCC2 cRNA in the presence or absence of wild-type 
KCC3 or KCC3-E289G cRNAs. KCC2 or KCC3 were then immunoprecipitated and the complex 
was analyzed by Western blot analysis using rabbit polyclonal anti-KCC2 or anti-KCC3 
antibodies. Immunodetection of KCC2, KCC3 and IgG are indicated on the right of the panels. 
Note that both KCC2 (panel A) and KCC3 (panel B) when immunoprecipitated are observed as 2 
bands: unglycosylated and glycosylated forms. Experiment was repeated once and yielded similar 
data. 
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Figure 9. Evidence for dominant-negative effect of KCC3 on KCC2 function. 
 
A) Xenopus laevis oocytes were injected with KCC2 cRNA in the presence or absence of wild-
type KCC3 or KCC3-E289G cRNAs. Three days following injection, K
+
 influx was measured 
under isosmotic conditions where only KCC2 function is active, or under hyposmotic conditions 
where both KCC2 and KCC3 function are stimulated. Bars represent mean ± S.E.M. (n = 20–25 
oocytes). Flux is expressed in nmoles K
+
/oocyte/h. 
(
*
)
 P < 0.01 (ANOVA) compared with KCC2 
alone under isosmotic condition, 
(∑)
 P <0.01 (ANOVA) compared with KCC2 alone under 
hyposmotic solution. Arrow indicates the anticipated flux mediated by the combined activity of 
KCC2 and KCC3. This is a representative experiment. Each condition (bar) was reproduced 
multiple times. B) K
+
 influx was measured under hyperosmotic conditions in oocytes injected 
with NKCC1 cRNA in the presence or absence of KCC3-E289G cRNA. Bars represent mean ± 
S.E.M. (n = 20–25 oocytes). Flux is also expressed in nmoles K+/oocyte/h. 
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Figure 10. Evidence for dominant-negative effect of KCC3 on KCC2 trafficking. 
 
Xenopus laevis oocytes were injected with KCC2 in the presence or absence of wild-type KCC3 
or KCC3-E289G cRNAs and membrane fractions were isolated using a silica cross-linking 
method. Membrane proteins and whole oocyte lysates were subjected to Western blot analysis 
using rabbit polyclonal anti-KCC2 or anti-KCC3 antibodies. Experiment was reproduced 3 times. 
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Figure 11. Evidence for dominant-negative effect of KCC3 on KCC2 trafficking and 
function. 
 
Xenopus laevis oocytes were injected with KCC3, KCC3-E289G, or both. A) Membrane fraction 
was isolated using a silica based cross-linking method and membrane proteins and whole oocyte 
lysates were subjected to Western blot analysis using rabbit polyclonal anti-KCC2 or anti-KCC3 
antibodies. B) K
+
 influx was measured under hyposmotic conditions. C) K
+
 influx generated by 
KCC3-KCC3 and KCC3-KCC3-E289G concatamers. Bars represent mean ± S.E.M. (n = 20–25 
oocytes). Flux is expressed in nmoles K
+
/oocyte/h. *P<0.001 (ANOVA) compared with KCC3 
controls. Experiment was performed 6 times with similar data. 
 
 
 
39 
 
the KCC3-E289G mutation did not poison the endoplasmic reticulum. 
KCC3-E289G mutant prevented wild-type KCC3 to reach the plasma membrane (Figure 
10A) which resulted in dominant-negative effect on KCC3 function (Figure 10B). As K- 
Cl cotransporter likely functions as homodimers, we forced dimerization through the use 
of concatamers or mRNA molecules encoding two KCC3 cotransporters, linked head to 
tail and separated by a 9-glutamine linker. As seen in Figure 11C, concatamers made of 
wild-type KCC3 molecules were functional, whereas addition of mutant KCC3-E289G 
monomer downstream of a wild-type monomer eliminated the function of the dimer. 
The lower molecular size of the KCC3-E289G band observed in Figure 10 indicates a 
defect in glycosylation. To further substantiate this defect, we transfected HEK 293FT 
cells with wild-type and mutant KCC3 and observed absence of larger molecular weight 
products in the KCC3-E289G mutant (Figure 12A). As KCC3 is natively expressed in 
Chinese hamster ovary (CHO) cells, we took advantage of mutant CHO cell lines (Figure 
12) to evaluate the extent of the KCC3-E289G glycosylation deficit. As shown in Figure 
13A, the signal from the KCC3-E289G mutant is similar to the signal shown in the CHO 
Lec8 and Lec1 samples, indicating early glycosylation deficit. Treatment with 
tunicamycin, which blocks the synthesis of all N-linked glycoproteins (Figure 13A), and 
PNGase, an enzyme that cleaves asparagine-linked mannose rich oligosaccharides 
(Figure 13B), slightly reduced the molecular size of the KCC3-E289G band, indicating 
the presence of a core glycosylation. These data are consistent with the protein being 
partially modified in the endoplasmic reticulum. Staining of HEK 293FT cells transfected 
with wild-type KCC3 (Figure 14A-F)  
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Figure 12. N-Glycolsylation deficiency of the KCC3-E289G mutant. 
 
A) Western blot analyses of KCC3-E289G mutant in HEK 293FT cells and Xenopus laevis 
oocytes compared to wild-type KCC3 in HEK 293FT cells, wild-type and mutant CHO cells, and 
Xenopus laevis oocytes, using rabbit polyclonal anti-KCC3 antibody. CHO-Lec1 cells have 
mutation in N-acetylglucosaminyl transferase, whereas CHO-Lec8 and CHO-Lec2 have deficient 
galactose and sialic acid transporters, respectively. Two independent experiments are shown. 
Experiment was performed 4 times. B) Scheme represents the main steps in N-linked 
oligosaccharide biosynthetic pathway. First, core Glc-Nac-Glc-Nac-Man with branched mannose 
residues are added to the Asparagines in the ER. In the Golgi, mannose molecules are replaced by 
acethylglucosamyl groups, followed by the addition of galactose and sialic acid groups. These 
steps require the availability of galactose and sialic acid in the cells, which is prevented in the 
mutant CHO cells by elimination of specific transporters. 
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Figure 13. N-Glycolsylation deficiency of the KCC3-E289G mutant. 
 
A) Western blot analysis of wild-type KCC3 and KCC3-E289G mutant in HEK 293FT cells 
treated with tunicamycin (exposed to 10 µg/ml for 18 hours). B) Western blot analysis of wild-
type KCC3 and KCC3-E289G mutant proteins isolated from Xenopus laevis oocytes and treated 
with PNGase (0.25U, 12 h at 37°C). The membranes were exposed to a rabbit polyclonal anti-
KCC3 antibody. The experiment was repeated once with identical data. 
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Figure 14. Evidence for KCC3-E289G localizing in the endoplasmic reticulum. 
 
HEK 293FT cells were transfected with wild-type KCC3 (A–F) or KCC3-E289G mutant (G–L). 
Two days post- transfection, the cells were fixed with paraformaldehyde, treated with saponin, 
and exposed to rabbit polyclonal anti-KCC3 and mouse monoclonal anti-PDI antibodies followed 
by cy3-conjugated anti-rabbit and Alexa Fluor–conjugated goat anti-mouse antibodies. Focal 
plane images of KCC3 signal (A, D, J, G), ER marker signal (B, E, H, K), and combined signals 
(C, F, I, L). Bar = 5 µm. 
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demonstrates cotransporter localization in the plasma membrane and intracellular 
compartments but with minimal co-localization with the ER marker (PDI). However, the 
KCC3-E289G (Figure 14G-L) mutant revealed strong co-localization with PDI (Figure 
14G-L).  Using a subcellular fractionation protocol, we were able to confirm in HEK 
293FT cells that the KCC3-E289G mutant does not make it to the plasma membrane, but 
is exclusively located in intracellular organelles, whereas wild-type KCC3 signal is 
observed both in membrane and intracellular organelles (Figure 15). No KCC3 signal is 
observed in water-injected oocytes (over 5 experiments). Note the presence of a sizable 
fraction of wild-type KCC3 and KCC3-E289G associated in the nuclear fraction, this 
signal might partially originate from nuclei-associated endoplasmic reticulum, as PDI 
signal was also observed in the nuclear fraction.  
Because the glutamic acid residue is highly conserved within cation-chloride 
cotransporters, we examined the effect of mutating the corresponding residues in KCC2 
and NKCC1. As seen in Figure 17, mutation of KCC2 glutamic acid residue 201 into 
glycine completely abrogated KCC2 function under both isosmotic and hyposmotic 
conditions. Interestingly, the glutamic acid residue could not be substituted with a 
negatively charged aspartic acid residue. In contrast, there was minimal effect of 
mutating the corresponding glutamic acid residue in NKCC1, as cotransporter function 
was similar for mutants NKCC1-E383G or E383D when compared to wild-type NKCC1 
under isosmotic conditions. To demonstrate that NKCC1 was expressed in the plasma 
membrane to similar levels, we utilized a constitutively-active form of SPAK to activate 
the cotransporter (Gagnon and Delpire, 2012; Gagnon et al., 2011). Under SPAK 
activation, the levels of cotransporter activity were similar between wild-type and mutant  
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Figure 15. Sub-cellular localization of KCC3 and KCC3-E289G in HEK 293FT cells. 
 
HEK 293FT cells were transfected with wild-type KCC3 or KCC3-E289G mutant. Two days 
post-transfection, the cells were treated with digitonin to extract proteins from cholesterol-rich 
(plasma) membranes (membrane/cytosol fraction), followed by NP40 treatment to isolate proteins 
from ER/Golgi fraction, followed by deoxycholate + SDS detergents to isolate proteins from 
nuclear fraction. Western blots were probed with rabbit polyclonal anti-KCC3 and mouse 
monoclonal anti-PDI and anti-GAPDH antibodies. Experiment was reproduced at least 5 times 
with similar data. 
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Figure 16. Effect of E289G-like mutations in KCC2 and NKCC1. 
 
K
+
 influx was measured through unidirectional 
86
Rb tracer uptake in oocytes injected with water, 
wild-type KCC2 or KCC2-E201G or KCC2-E201D mutant cRNAs, and wild-type or NKCC1-
E383G or NKCC1-E383D mutant cRNAs. Uptakes were measured under isosmotic (200 mOsM) 
and hypotonic (100 mOsM) solutions for KCC2 and under isotonic and hypertonic (265 mOsM) 
solutions for NKCC1. Bars represent mean ± SEM (n = 20–25 oocytes). Fluxes are expressed in 
nmoles K
+
/oocyte/h. (*) Denotes statistical significance with P < 0.001 (ANOVA followed by 
Tukey-Kramer Multiple Comparisons Test). Experiment was done once. 
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NKCC1cotransporters. However, there was a significant reduction in cotransporter 
activation in the mutants versus wild-type NKCC1 under hyperosmotic conditions. 
  
4. Discussion 
K-Cl cotransporters are encoded by four distinct genes each of which generates many 
variants due to the use of alternative promoters and alternative splicing (For reviews, see 
(Hebert et al., 2004; Payne, 2009)). Published Western blot data indicate the presence of 
dimers or oligomers and functional studies have demonstrated that K-Cl cotransporters 
form homo-dimers. An intriguing consensus emerging in the field of cation-chloride 
cotransporter is that cells often co-express multiple isoforms of the K-Cl cotransporter. 
While this might not necessarily be too surprising for an bipolar epithelial cell that might 
express one form of the cotransporter on the apical membrane and another on the 
basolateral membrane, or even for a neuron which might express one form in dendritic 
spines and another at the cell body, this observation still raises the intriguing possibility 
that one isoform might affect the expression and/or function of another. To address this 
possibility, we made use of a functional cotransporter (KCC3), a non-functional 
cotransporter mutant (KCC3-E289G), and a second functional cotransporter (KCC2) to 
examine the possibility of hetero-dimerization and co-regulation. The present studies 
were performed with the specific aim to examine whether a non-functional but full-length 
cotransporter affects the function of an active cotransporter. We started our studies with a 
KCC3 mutant that fails to demonstrate hypotonic-stimulation of K
+
 influx when 
expressed in Xenopus laevis oocytes. As the residue is located in an extracellular loop, it 
47 
 
is unlikely that the deficit is due to regulation by intracellular signaling/regulatory 
proteins, such as kinases or phosphatases. 
Co-immunoprecipitation experiments revealed that both wild-type and KCC3-E289G 
mutant interact with KCC2 when co-injected in oocytes. These data indicate that not only 
KCC2 and KCC3 can be co-expressed in neurons (Le Rouzic et al., 2006; Pearson et al., 
2001; Shekarabi et al., 2011), but that they are able to form oligomers. Functional data 
argue that expression of KCC3 affects KCC2 function or vice-versa, irrespective of the 
nature of the KCC3 clone co-expressed (wild-type versus mutant). Indeed, it was striking 
that K
+
 influx measurements were never additive when both cotransporters were 
expressed in the oocytes. As our experiments were controlled for the level of cRNA 
injected, it was clear that these effects were true dominant-negative effects and not 
related to RNA saturation in the oocytes. To explain these data, we examined expression 
of the cotransporters at the cell surface. Instead of biotinylation, we utilized a method that 
was developed specifically for Xenopus laevis oocytes and which was shown to be of 
high sensitivity (Leduc-Nadeau et al., 2007). Protein expressed at the plasma membrane 
were cross-linked to silica and simply isolated by centrifugation. Indeed, after washing 
excess silica, lysing the oocytes, pelleting and washing the silica, wild-type KCC2 and 
KCC3 protein were readily observed by Western blot analysis. In contrast, no signal was 
observed from oocytes expressing KCC3-E289G, indicating that the mutant cotransporter 
does not reach the plasma membrane, or if some of it reaches the membrane, it is below 
the level of detection of the silica method. Co-expression of KCC3-E289G with KCC2 
resulted in absence of KCC2 expression in the oocyte membrane, whereas co-expression 
of wild-type KCC3 with KCC2 resulted in decreased expression of KCC2 in the 
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membrane. These data indicate that the mutant KCC3 protein prevents proper trafficking 
of KCC2 to the cell surface. The fact that expression of wild-type KCC3 also affects 
expression of KCC2 is puzzling. This indicates that when the two cotransporters interact, 
trafficking of this hetero-dimer to the plasma membrane is impaired. However, this 
interaction would only take place when mRNA molecules are translated simultaneously 
and the dimer forms in the endoplasmic reticulum. Thus, to prevent this specific 
mechanism of regulation, cells might have ways to separate translation spatially and/or 
temporally in order to express full complements of each transporter to the plasma 
membrane.  
Our data indicate that mutation of extracellular glutamic acid residue 289 into a glycine 
impairs trafficking of KCC3 to the plasma membrane. If trafficking of KCC3-E289G to 
the cell surface is fully prevented, this by itself explains the absence of function. We 
attempted to ‘force’ the transporter to the cell surface by using a molecular chaperone 
utilized to rescue trafficking of the CFTR-Δ508 mutation (Rubenstein et al., 1997; Zeitlin 
et al., 2002). Incubation of the oocytes with 2.5 mM 4-phenylbutyrate for 3 days during 
translation, had no effect on trafficking and function of the mutant KCC3 cotransporter 
(1002 ± 62 pmoles/oocyte/h (n = 26) for wild-type KCC3 alone versus 1129 ± 42 (n = 26) 
for wild-type KCC3 in oocytes treated with 4-PBA and 86 ± 12 pmoles/oocyte/h (n = 26) 
for mutant KCC3 alone versus 90 ± 10 (n = 24) for mutant KCC3 in oocytes treated with 
4-PBA). Because the silica method likely has a detection threshold below which there is 
no cell surface detection, there is a possibility that some of the mutant cotransporter does 
reach the plasma membrane. If it is the case, this would indicate that the transporters that 
have reached the membrane are also functionally silent. The precise mechanism by which 
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a single substitution of a glutamic acid residue to a glycine at the end of transmembrane 3 
affects trafficking is unknown. It is tempting to speculate that the negatively charged 
residue at the end of the transmembrane domain affects the threading of the domain 
across the reticular membrane and that in turn affects the overall topology and folding of 
the protein. It is, however, important to note that the glutamic acid cannot be substituted 
by an aspartic acid, which also carries a negative charge (see Figure 16). We did not test 
additional amino acid substitutions in this study. It will be of interest to expand the 
analysis to other residues such as glutamine which has a side chain similar to glutamic 
acid and alanine which has a size similar to glycine. An independent confirmation which 
supports our observation that the transporter is not properly trafficked to the plasma 
membrane comes from the migration pattern of the mutant KCC3 protein in an 
acrylamide gel. Western blot analysis data show absence of a broad band typical of a 
glycosylated membrane protein for the KCC3-E289G mutant. Treatment of protein 
lysates isolated from oocytes expressing KCC3-E289 with PNGase demonstrated a small 
shift in molecular size, indicating that the core glycosylation (or addition of mannose 
sugars) had taken place in the KCC3-E289G cotransporter mutant. Comparison of the 
glycosylation pattern of KCC3-E289G in HEK 293FT cells or in Xenopus laevis oocytes 
with the pattern of native KCC3 in CHO cells with mutation in glycosylation genes 
revealed deficits in the early glycosylation steps that typically occur in the Golgi. This 
would indicate that trafficking of the mutant transporter might be arrested in the 
endoplasmic reticulum or early Golgi. This conclusion was further supported by 
immunofluorescence data and cell fractionation data that demonstrate co-localization of 
the KCC3-E289G mutant with the ER marker, PDI. Thus, we have uncovered a glutamic 
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acid residue in KCC3 which when substituted into a glycine affects glycosylation and 
trafficking of the cotransporter to the plasma membrane. As the mutant cotransporter is 
full-length it can interact in the ER with wild-type cotransporters (KCC3 or KCC2) and 
prevent their trafficking as well. Control experiments with co-injection of KCC3-E289G 
with NKCC1 revealed that trafficking is impaired due to interaction of KCC monomers 
instead of ER poisoning. As the interaction of K-Cl cotransporters occurs at the C-
terminal tail (Simard et al., 2007), we also tested whether trafficking of KCC2 would be 
affected by a transporter lacking part of the C-terminal tail. Indeed, co-expression of 
KCC2 in oocytes with twice the amount of RNA encoding KCC3-T813X, the Quebec 
HSMN/ACC mutant, had no effect on the function of wild-type KCC2 (2777 ± 162 (n = 
25) for KCC2 + KCC3-T813X versus 2997 ± 180 (n = 23) for KCC2 alone), indicating 
that the absence of a C-terminal tail prevents the KCC3-T813X mutant to interact with 
wild-type and affects its trafficking. 
As the KCC3 glutamic acid residue 289 is conserved within cation-chloride 
cotransporters, we wondered if mutation of the corresponding residue in other K-Cl 
cotransporters or even one of the Na-K-2Cl cotransporter would also affect their function. 
Interestingly, KCC2 function was completely eliminated in the KCC2-E201G mutant, 
whereas function of NKCC1 was only partially affected in the NKCC1-E383G mutant. 
These data indicate that the residue is far more essential to K-Cl cotransport than Na-K-
2Cl cotransporter function. Because the levels of isosmotic transport (under control 
conditions and SPAK-activated conditions) are identical in the two NKCC1 mutants 
versus wild-type, it is likely that trafficking of NKCC1 is not affected by the mutations. 
In contrast, the function of NKCC1 is significantly reduced under hyperosmotic 
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conditions. These data are in agreement with a previous study showing that the second 
extracellular loop is involved in the sensitivity of NKCC1 and NKCC2 to 
hyperosmolarity (Gagnon and Delpire, 2010). 
In conclusion, our results show that E289 in KCC3 and E201 in KCC2 are essential 
residues for proper trafficking of the cotransporters, respectively. Experiments performed 
in Xenopus laevis oocytes and mammalian HEK 293FT cells revealed that the KCC3-
E289G mutant cotransporter is stuck in the endoplasmic reticulum and likely receives 
only the core mannose glycosylation. Our results also demonstrate that hetero-
dimerization of KCC2 and KCC3 is possible and that co-expression of one cotransporter 
affects expression of the other. These data also indicate that expression of a full-length 
mutant cotransporter, even if non-functional, might have dominant-negative effects on 
other related cotransporters, suggesting the possibility that single residue mutations that 
do not lead to protein truncation might lead to different phenotypes than knockout of the 
protein. 
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III. Characterization of KCC3-E289G mutant in vivo 
 
1. Introduction  
Peripheral neuropathy with or without agenesis of the corpus callosum (Andermann 
syndrome or ACCPN) is an autosomal recessive disorder characterized by a progressive 
sensorimotor neuropathy, general learning disability, as well as bone deformities (facial 
abnormalities and fused fingers) (Dupre et al., 2003) . This autosomal recessive 
hereditary disease is caused by genetic mutations in the SLC12A6 gene, which encode 
the potassium-chloride co-transporter 3(KCC3). During the study for similar genetic 
diseases caused by mutations of this family, such as the Gitelman syndrome caused by 
mutations in the SLC12A3/NCC gene (OMIM 2638000) and Bartter syndrome which is 
caused by mutations in the SLC12A1/NKCC2 gene (OMIM 601678), many pathogenic 
mechanisms have been established, such as biosynthesis, trafficking, conductance, 
mutant protein degradation; however, even though several KCC3 knock out mouse 
models have been established to study the development of ACCPN disease, the specific 
pathogenic mechanism remains to be understood. 
Currently there are 8 KCC3 mutations found in ACCPN patients, including seven 
truncating nonsense mutations, and one missense mutation (Figure 17). The majority are 
truncating mutations which lead to premature termination of the protein, resulting in 
various length truncations of the carboxyl terminal fragment of the protein. The C-
terminal of KCC3 has been shown to interact with creatine kinase B, an important kinase 
for ATP generation and KCC3 activation. Absence of the C-terminal domain leads to 
systematical disruption of KCC3 activation and proper trafficking to the plasma  
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Figure 17. Location of KCC3 mutations associated with ACCPN. 
 
Most ACCPN mutations results in truncation of the protein. The distal c-terminal portion contains 
a creatine kinase B domain (CK-B). Interaction with CK-B in the C-terminus is required for 
normal KCC3 function. 
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membrane as well (Inoue et al., 2006; Salin-Cantegrel et al., 2008). Among the two 
missense mutations, the R207C mutation showed an enhanced dimerization presence in 
mammalian cells and prevented the normal trafficking to the plasma membrane, while the 
missense G539D mutation was found in a compound heterozygous mutation:  a maternal 
missense mutation c.1616G > A (p.G539D) and a paternal splice mutation c.1118 + 1G > 
A,  which eventually leads to a truncated protein as well. Therefore, there is not a known 
natural KCC3 mutation which still produces a full length that causes HSN/ACC. 
As discussed in the previous chapter, during the process of cloning the mouse KCC3 
cDNA, we came across a mutation resulting in the substitution of glutamic acid residue 
E289 into a glycine (E289G). This negatively charge residue, located at the end of trans-
membrane domain 3 (TM3) or beginning of extracellular loop 2 (ECL2) is highly 
conserved in all mammalian cation-chloride cotransporters. Although the KCC3-E289G 
mutant was non-functional when expressed in Xenopus laevis oocytes, function was 
restored when the residue was mutated back into a glutamic acid. The KCC3-E289G 
protein is expressed as a full-length protein in Xenopus laevis oocytes and mammalian 
cells (Ding et al., 2013).  
When we obtained the KCC3-E289G mutant, we realized that this particular KCC3 
mutation may help us understand the detailed pathogenic properties of KCC3 leading to 
HSN/ACC. In this study, we created two transgenic lines of KCC3-E289G knockin mice 
where the wild-type KCC3 was replaced with the E289G mutation. We found that one of 
the line generated showed a significant locomotor deficit in the rotarod test, whereas the 
second line failed to demonstrate this phenotype. Immunostaining studies on isolated 
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dorsal root ganglion neurons slices, demonstrated that the KCC3-E289G mutant protein 
did not reach properly the plasma membrane. 
 
2. Methods 
Generation of the floxed SLC12A6 and knock-in mouse. We replaced the mouse wild-
type Slc12a6 gene by inserting loxP sites around exon 7 (131 bp), followed by a 
neomycin resistance gene cassette flanked by Frt sites. The targeting vector was 
constructed using recombineering techniques to drop the short 5’ end and long 3’ end 
arms of recombination from BAC clone bMQ-302F12 (Geneservice Ltd, Cambridge, UK) 
into a vector containing 3 loxP sites, 2 Frt sites, and a PGK-driven neomycin resistance 
gene cassette. Briefly, a 2526 bp fragment (short arm) was dropped from the BAC clone 
between unique sites located upstream of the first loxP site. A small PCR fragment 
consisting of exon 7 surrounded by short intronic sequences was then ligated downstream 
of the first loxP site. Finally, a larger 7.5 kb fragment (large arm) was dropped from the 
BAC clone downstream of the last loxP site. The construct, verified by map digest and 
sequencing, was linearized using NotI. TL-1 ES cells were then electroporated with the 
linearized construct and grown on fibroblast feeder cells in Dulbecco’s Modified Eagle 
Medium (D-MEM) medium supplemented with 15% fetal bovine serum, 50 mg/ml 
gentamicin, 1000U/ml LIF, 90 mM β-mercaptoethanol, and 0.2 mg/ml G418. Three 
hundred and fifty independent neomycin-resistant colonies were picked and grown in 96-
well plates on feeder layer, expanded them and analyzed for the presence of the mutant 
gene by performing Southern blot analysis using genomic DNA digested with SpeI and 
hybridized with a 
32
P-labeled probe consisting of 406 bp downstream of the right arm of 
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recombination. Seven positive clones were identified and one clone (5H6) was injected 
into C57BL/6J blastocysts.  Two chimeric males (> 90% brown fur) were mated with 
C57BL/6J females and germline transmission was obtained. Since these mice carried one 
allele containing the neomycin-resistance gene cassette (3 loxP), they were mated with 
FLPeR mice (obtained from Susan Dymicki, Harvard and backcrossed in our laboratory 
for >10 generations in C57BL/6J background) to eliminate the neomycin-resistance gene 
cassette. 
Accelerated Rotarod. The accelerated rotarod test was performed as previously 
described (Geng et al., 20010). Briefly, neuromotor coordination task was performed 
using an accelerating rotating cylinder (model 47600: Ugo Basile, S.R. Biological 
Research Apparatus, Comerio, Italy). The cylinder was 3 cm in diameter and was covered 
with scored plastic. Mice were confined to a 4 cm long section of the cylinder by gray 
Plexiglas dividers. Three to five mice were placed on the cylinder at once. The rotation 
rate of the cylinder increased over a 5 min period from 4 to 40 rpm. The latency of each 
mouse to fall off the rotating cylinder was automatically recorded by the device. Mice 
that remained on the rotarod during the 300 s trial period were removed and given a score 
of 300 s. The test was performed for three trials a day for 3 consecutive days. 
Open field. This test was also executed as described earlier (Geng et al., 2010). 
Exploratory and locomotor activities were tested using an open-field activity chamber 
surrounded by a Plexglas enclosure within sound-attenuating cubicles (ENV-022MD-027; 
Med Associates, Inc., St. Albans, VT). The mice were placed in the center of the open 
field and their activity was monitored for 60 min. The test was performed at ambient 
room temperature (25 ◦C), moderate light (60 lx), and background noise (80 dB). 
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Distance traveled and time spend in the periphery (thigmotaxis) of the chamber were 
quantified by the number of beam crossings. 
DRG neuron isolation. Wild-type and homozygote mice were killed by cervical 
dislocation. DRGs were dissected from the lower thoracic to mid-lumbar regions of the 
vertebral column and placed in 0.1M PBS. The connective tissue sheath around the 
ganglia was removed, and DRGs were minced two to three times with iridectomy scissors. 
The minced DRGs were then placed in a flask containing 5 ml of 4% (w/v) solution of 
PFA (Sigma Aldrich) in 0.1 M PBS (4 °C, pH 7.4) over night.  
Dorsal root ganglia fixation and staining. Dorsal root ganglia were dissected from the 
lower thoracic to mid-lumbar regions of the vertebral column and were placed in a 4% 
(w/v) solution of PFA (Sigma Aldrich) in 0.1 M PBS (4 °C, pH 7.4) overnight . 
Following fixation, DRG neurons were transferred to a 30% (w/v) sucrose solution in 0.1 
M PBS for 24 hours~48 hours before embedding into OCT(OCT
®
) blocks. The OCT 
blocks were stored at −20°C before being transferred for cryostat sectioning. Sections 
were cut 10 μm thick in the cryostat microtome at −20°C and were immediately 
transferred to a room temperature microscope slide by touching the slide to the tissue. 
The slides were stored at −20°C for further histology study. Routine H&E staining was 
performed for general histology. For immunostaining, the slides were defrost in room 
temperature for 10 min then permeabilized with 0.1% Triton X-100 for 5 min. After 
washing in PBS for 2x5 min, slides were then blocked for 30 min with 1% BSA in PBS 
with 1% goat serum. Then primary antibodies (anti-PDI antibody (Abcam, Ab27043 
1:200), anti-KCC3 antibody (Delpire lab, 1:250), anti-T4 NKCC1 antibody 
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(Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, IA), 1:200)) 
were applied in 1%BSA with PBS at 4°C overnight. On the second day, the slides were 
washed twice separately by high salt PBS and regular PBS, and then blocked with 1% 
BSA in PBS with 4% goat serum for 30 min. Then secondary antibodies (100 ul, Cy3 
conjugated anti-rabbit antibody (1:1000, Jackson Immunochemicals) and Alexa Fluor 
anti-mouse IgG (H+L) (1:400, Invitrogen) were applied and incubated for 60 min at room 
temperature. Cells were then incubated with the DNA dye TO-PRO-3 (Invitrogen) at a 
dilution of 1:300 in PBS for 15 min. Slides were then washed 3 times for 10 min each in 
PBS, mounted in Vectashield mounting medium (Vector Laboratories, Burlingame, CA), 
and examined using fluorescence microscopy. Fluorescence signal was visualized using a 
Carl Zeiss LMS 510 META confocal microscope. 
 
3. Results  
3.1. Lethality of the first KCC3-E289G homozygote mouse line 
In order to create a KCC3-E289G knock in mouse, we generated a targeting vector that 
included the E289G mutation within exon 7 of the Slc12a6 gene. Exon 7 was also flanked 
by loxP sites, which we will see later was a very useful addition (Figure 18A). Several ES 
cell clones carrying the mutation were identified and one clone (5H6) was injected into 
C57BL/6J blastocysts. Two chimeric males were obtained and mated to C57BL/6J 
female mice. After germline transmission, elimination of the neomycin-resistance gene 
cassette by crossing mutant mice with FlpE mice, a 3 kb fragment was PCR amplified to 
demonstrate recombination in the proper locus. Sequencing of the fragment revealed 
correct 5’ sequence and presence of the mutated exon and of the two loxP sites at the 3’ 
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end of the fragment (Figure 18B), demonstrating recombination in the proper KCC3 
locus. Breeding of one heterozygous male with one heterozygous female resulted in 9 
pups with 6 heterozygotes and 3 wild-types, no homozygotes (Figure 18C). Sequencing 
of the PCR product from 1 heterozygote animal revealed the presence of the E289G 
mutation as well as the wild-type allele (Figure 18D). Altogether breeding of 11 
heterozygous males and females resulted in no mice that were homozygous for the 
mutation. Out of 86 pups, there were 64 heterozygous and 22 control mice (Table 2). 
Note that while we genotyped the mice at age P21, we observed the pups daily from birth 
to P21 and genotyped any pup that died during this postnatal period.  
This result infers embryonic lethality. In order to understand what caused the embryonic 
lethality phenotype seen in the homozygous mutant mice, we dissected the mouse 
embryos in different stages and genotyped these embryos. Surprisingly, no homozygous 
mutant embryos were detected as early as E3.5 (embryonic day 3.5), which still 
corresponds to the blastocyst stage (Table 2).  
Because the embryonic lethality prevented us from studying the KCC3-E289G mutant 
protein in vivo, we devised alternative ways to proceed without obtaining the 
homozygous mutants. We crossed the heterozygous KCC3-E289G mouse with our KCC3 
null mice which are described in Howard et al. (Howard et al., 2002). These mice have 
exon 3 permanently removed from the Slc12a6 gene. In a first breeding scheme, we 
obtained 6 offsprings, among which we identified two pups carrying one copy of the 
E289G allele and one copy of the null allele (KCC3
-/E289G
). Because the null allele does  
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Figure 18.  Targeting construct of KCC3 E289G knock in. 
 
A. Schematic representation of the Slc12a6 (KCC3) gene around exon 5-11. Highlighted are two 
SphI restriction sites separated by 8 kb genomic sequence. B. Construct containing a 2950 bp 
genomic DNA sequence representing the 5’ arm of recombination loxP sites flanking exon 7, 
followed by a PGK-driven neomycin resistance gene cassette flanked by FRT sites, and a 7500 bp 
3’ arm of recombination . C. Genotyping of 2 litters of pups from heterozygous breeding showing 
PCR fragments from wild-type and mutant alleles. D. DNA Sequencing showing the A to G 
mutation resulting in the substitution of glutamic acid residue E289 into a glycine (E289G).  
 
 
 
 
 
 
61 
 
Table 2. Breeding revealed absence of E289G homozygous mice. 
 
Genotyping # of 
females 
Pups per 
female 
Total 
pups 
Heterozygous Control Homogyous 
P21 11 7.8 86 64 22 0 
E16.5 1 9 9 6 3 0 
E12.5 2 7 14 7 7 0 
E8.5 2 7.5 15 * * * 
E3.5 5 12.4 48 36 12 0 
 
 
 
Breeding of 11 heterozygous males and females resulted in no mice that were homozygous for 
the E289G mutation. Analysis of embryos from 12.5 -16.5 days also revealed absence of 
homozygotes. Finally, isolation of blastocysts at E3.5 days demonstrated early lethality. Lower 
right corner: distribution of genotypes for all embryonic and postnatal ages. * All embryos were 
genotyped as heterozygous, suggesting that embryo tissues might be contaminated with tissues 
from the mother.  
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not produce any KCC3 protein, these animals only expressed KCC3-E289G. As these 
two animals were viable, we crossed additional animals and obtained a small cohort of 
mice to assess their locomotion phenotype using the rotarod (Figure 19). Interestingly, no 
locomotor phenotype characteristic of KCC3 knockout mice was observed. 
To determine if the lethality is caused by the mutated (E289G) exon, or to other 
unforeseen events related to the recombination in embryonic stem cells, we made use of 
the loxP sites flanking the mutated exon 7. To eliminate the exon, we crossed the KCC3-
E289G mice with E2a-CRE transgenic mice, which express the recombinase in the one 
cell zygote. Without the mutated exon, homozygous mice should be viable and exhibit 
the ACCPN phenotype, as they are KCC3 null mice.   
Heterozygous 1 loxP mice were identified by genotyping and bred together to generate 
homozygous mice. However, again no homozygous mice were found among the first 16 
pups generated (11 wild-types and 5 heterozygotes), indicating that deletion of exon 7 did 
not rescue the lethality phenotype. We concluded that the embryonic lethality was not 
caused by the mutated exon but by some other events that occurred during targeting.   
We therefore went back to the frozen embryonic stem cell clones and injected an 
independent clone (5G8) into C57BL/6J blastocysts. After germline transmission and 
crossing again with FlpE mice to eliminate the neomycin resistance gene cassette, we 
obtained a new line of KCC3-E289G heterozygous mice. The exon was PCR amplified 
and sequenced to verify the presence of the mutation. Breeding of heterozygous males 
and females generated viable mutant homozygous (KCC3
E289G/E289G
) mice. Initial 
observation did not show any posture or locomotor phenotype. However, when placed on 
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Figure 19. Absence of locomotor phenotype in KCC3
-/E289G
 double mutant mice. 
 
Accelerated rotorod test (4 to 40 rpm, 5 min) performed in control (KCC3
f/f
) and KCC3
-/E289G
 
double mutant mice. Test was given three times a day for 3 consecutive days. The latency to fall 
from the rotating rod to the platform was measured in seconds. N = 6 mice per group. 
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the accelerated rotarod, the animals demonstrated a significant locomotor deficit (Figure 
20A). No significant phenotype was observed with the open field activity test (Figure 
20B). 
Most of other KCC3 mutations affect the plasma membrane localization of the mutant 
transporter, preventing the normal trafficking to the membrane with significant retention 
of the protein in the endoplasmic reticulum (ER). In order to understand whether this is 
also the case for E289G mutation, we isolated DRG neurons from the KCC3
E289G/E289G
 
mice and performed immunostaining with the plasma membrane marker NKCC1 
antibody, the KCC3 antibody and the nucleus marker TO-PRO
®
-3.  As shown in Figure 
21, KCC3 in controls tissues were localized outside the ER marker (PDI = protein 
disulphide isomerase), while in many cells from the knock in mice, the KCC3 was 
retained in the ER and co-localized with the PDI marker. This result demonstrated that 
the mutant KCC3E289G protein showed the same trafficking deficit, as we observed in 
vitro (see Chapter 3).  
 
4. Discussion  
KCC3 is expressed in many different tissues and organs in both mice and humans. By 
functioning as an electroneutral transporter of potassium and chloride ions, KCC3 plays 
important roles in epithelial chloride transport, cell volume regulation, and intracellular 
Cl
-
 homeostasis, thereby potentially affecting neuronal excitability. All the known KCC3 
mutations in ACCPN patients led to either truncated proteins or proteins which are not 
properly folded and failed to express, therefore we do not know whether the neuropathy 
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Figure 20. KCC3E289G knock in mice exhibit strong locomotor deficit. 
 
A, Data were analyzed using paired t-test. The difference between the two groups was highly 
significant (P < 0.001, t = 9.986, df =17). B, Mice were placed in open field chambers for 60 min. 
Total distance traveled was examined. Two tailed t-test demonstrated a P value of 0.2966 (t = 
0.9270, df = 17, non-significant). N = 10 mice per group. 
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Figure 21. KCC3-E289G mutant protein did not reach the plasma membrane. 
 
A-C. Longitudinal sections of DRG neurons from wild-type (n=3) mice were analyzed using 
immunofluorescence antibody against NKCC1 T4 (green, A&B), ER marker PDI (green, C) 
KCC3 (red, A-C) and nucleus marker TO-PRO
®
-3(blue, A&B). D-F. Longitudinal sections of 
DRG neurons from KCC3
E289G/E289G
 mice (n=3) and were analyzed using the same 
immunofluorescence antibody (D&E: green-NKCC1 T4, red-KCC3, blue-TO-PRO-3; F: green-
PDI, red-KCC3).  
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phenotype is due to the loss of K-Cl transport function of the protein, or due to the 
absence of the KCC3 protein per se. Indeed, it is possible that the cotransporter scaffolds 
a specific protein that is more directly involved with the neuropathy. Here, we introduce a 
novel mutation (E289G), which we showed in Chapter 2, disrupts the K-Cl transport 
function but expresses a full-length protein in heterologous expression systems. Using the 
transgenic knock-in technology, we created two separate lines of KCC3
E289G/E289G
 mice: 
the first one being embryonic lethal, while the second one produced viable homozygous 
mutants. 
For the first line, we demonstrated recombination within the proper locus by using long 
range PCR and sequencing. As the KCC3 null mouse is viable, it was unexpected to 
obtain embryonic lethality from a single amino acid substitution. Our first idea was that 
the mutation was causing the lethality possibly by affecting other cotransporters through 
direct interaction and dominant negative effects. This view was supported by the 
dominant-negative effects of KCC3-E289G that we observed on KCC2 function in 
Xenopus laevis oocytes (see Chapter 2). This hypothesis was, however, later dismissed 
when we eliminated the mutant exon and did not rescue the lethality phenotype. At this 
point, we do not understand the origin of the lethality. The construct used to introduce the 
mutation from the beginning (5’) of the short arm of recombination to the end (3’) of the 
long arm only covers a small portion of the Slc12a6 gene. Therefore, the deleterious 
event that occurred during recombination has to have occurred within the Slc12a6 gene, 
and any event leading to absence of protein expression should produce a viable mouse. If 
an additional event had occurred outside the Slc12a6 locus, it is likely that we would 
have been able to breed it out during our multiple crossings. Therefore, it is possible that 
68 
 
specific regions of the Slc12a6 gene have functions that are unrelated to the KCC3 
protein. For example, there could be some regulatory elements within introns that control 
other genes, e.g. microRNA, and these could have been altered during recombination.  
Of interest, we showed that substituting one of the two E289G alleles with a knockout 
allele (no exon 3) rescued the phenotype. Indeed, as with heterozygous mice that have a 
wild-type allele alongside the E289G mutant allele, mice carrying a knockout allele 
alongside the E289G mutant allele were also fully viable. In contrast to the heterozygotes, 
no KCC3 protein is produced from the knockout allele and therefore, only the KCC3-
E289G mutant is expressed in these mice. Experiments preformed in Chapter 2 
demonstrated that the mutant cotransporter does not make it to the plasma membrane and 
therefore does not promote transport of K
+
 (or Cl
-
). It was therefore unexpected to 
observe no locomotor deficit in these mice (Figure 19).  These data need to be reconciled 
with the data obtained with our second line of KCC3-E289G knock-in mice. In this case, 
a separate embryonic stem cell clone was used to generate the mice and viable 
homozygous knock-in mice were produced. These mice demonstrated a locomotor 
phenotype. While a statistically significant difference was observed between the mutant 
and control mice, the deficit was far less severe than the one observed in KCC3 knockout 
mice. These KCC3
E289G/E2899G
 knock-in mice are not very different from the double 
mutant KCC3
E289G/-
 mice, in that they also only express the mutated protein. The only 
difference is the copy number.  
At this point, we do not have a reason to explain why these seemingly similar mice 
behave so differently. The locomotor data need to be replicated with new cohorts of mice 
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preferentially generated at the same time. If the distinct phenotypes reproduced, it will 
mean that copy number is relevant. Expression of KCC3 by Western blot analysis and 
immunocytochemistry will need to be performed to assess level of protein expression and 
whether some mutated transporter successfully traffic to the membrane in the mice. This 
would be in contrast to what we observed in heterologous expression systems. It is 
difficult to understand why trafficking would happen in the mouse and not in 
heterologous expression systems, especially in frog oocytes as they are kept at a lower 
temperature and many transporter and channel protein mutants have been shown to traffic 
better at lower temperatures (Denning et al., 1992; Mall et al., 2004). If some of the 
KCC3 mutant proteins were to successfully traffic, they might function at the plasma 
membrane and therefore rescue the locomotor phenotype. If on the other hand the mutant 
transporter does not traffic, but is fully translated and some C-terminal parts interact with 
other proteins (even in the endoplasmic reticulum), this could explain why expression of 
KCC3-E289G could rescue the locomotor phenotype. Brain-type creatine kinase (CK-B), 
for instance, is known to bind to the large C-terminal domain of KCC3 (Salin-Cantegrel 
et al., 2008). CK-B is an isoform of creatine kinase, an enzyme that generates ATP and 
transfers a high-energy phosphate group from phosphocreatine to ADP, resulting in the 
regulation of the cellular ATP (Inoue et al., 2004). Several lines of evidence have shown 
that several membrane proteins form interaction with creatine kinase and affect its 
activity. Therefore, because of its location at the plasma membrane CK-B is thought to be 
producing the ATP that is required for the function of energy-driven transport proteins. A 
previous study showed that creatine kinase was required for swelling-activated 
potassium-chloride co-transport in red blood cells (Colclasure et al., 1995); other groups 
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have also reported a strong link between ATP and KCC activation (Lauf, 1983; Lauf et 
al., 1992; OrtizCarranza et al., 1996).  The detailed mechanism of KCC3 activation by 
ATP is very complex, but it is already known that the CK-B binding on KCC3 involves 
the last 18 amino acids of the transporter, a region that is lost in all ACCPN-associated 
truncation mutations, but remains intact in the KCC3-E289G protein (Ding et al., 2013). 
Interaction of CK-B with KCC3 could be important either at the endoplasmic reticulum 
level or if some of the mutant transporter makes it to the membrane.  
Among the HSN/ACC mutations, the R207C mutant was reported to be a full length 
protein, however, expressed at lower levels and also failing to reach the plasma 
membrane. The arginine at position 207 is located critically within a transmembrane 
domain and its replacement with a cysteine might completely affect the topology of the 
transporter. Furthermore, there was a dominant presence noted of KCC3-R207 dimers 
instead of monomer (Salin-Cantegrel et al., 2011). The possible misfolding, 
misclocalizaion, and dimerization of R207 mutant could have potentially affected 
interaction with a binding partner.  
Another interesting feature of ACCPN patients is that patients with a truncated KCC3 
mutation usually are associated with more severe clinical manifestations, while the 
patients bearing the missense mutation presents milder phenotype. Further investigation 
will be needed to further clarify the linkage between genotypes and phenotypes. For 
instance, beside the motor coordination deficiency, the KCC3 null mice also had 
phenotypes such as seizure susceptibility, hypertension, and gradual loss of hearing. Thus, 
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it would be worth investigating whether the loss of chloride function in these genetically 
modified animals was directly relevant to these phenotypes.  
In summary, our studies of the E289G mutation in mice gave ambiguous data with one 
line of mouse showing a completely normal locomotor function and the other line 
showing a locomotor deficit.  Whether this can be explained by copy number still needs 
to be resolved. Even though the E289G mutation is not found in nature, its study has 
shown it to be a useful tool to investigate the mechanisms by which disruption of KCC3 
leads to HSN/ACC. 
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IV. Cellular origin of ACCPN: Tissue-specific knockouts 
 
1. Introduction 
Peripheral neuropathy with or without agenesis of the corpus callosum (Andermann 
syndrome or ACCPN) is an autosomal recessive disorder characterized by a progressive 
sensorimotor neuropathy, general learning disability, as well as bone deformities (facial 
abnormalities and fused fingers) (Andermann et al., 1972; Labrisseau et al., 1984). 
Genetic linkage in fourteen families mapped the autosomal recessive disorder to 
chromosome 15q (Casaubon et al., 1996) and several mutations in SLC12A6, the human 
gene which encodes the K-Cl cotransporter-3 (KCC3), were later identified in 
HMSN/ACC patients (Boettger et al., 2003; Howard et al., 2002; Rudnik-Schöneborn et 
al., 2009; Uyanik et al., 2006). In a mouse model where the KCC3 gene was disrupted to 
produce a global knockout, an early onset and severe locomotor deficit similar to the 
crippling human peripheral neuropathy disorder was observed (Howard et al., 2002). The 
mice also developed high blood pressure (Boettger et al., 2003), age-related deafness 
(Adragna et al., 2004; Boettger et al., 2003), and renal dysfunction (Wang et al., 2003). 
At the ultra-structural level, KCC3-deficient mice exhibited axonal and peri-axonal 
swelling, suggesting both neuronal and Schwann cell defects (Byun and Delpire, 2007).  
In a recent study, Shekarabi et al used a synapsin 1 promoter-CRE mouse to drive 
deletion of KCC3 in neurons, and demonstrated that loss of neuronal KCC3 reproduced 
the neuropathy phenotype observed in the KCC3 knockout mouse (Shekarabi et al., 2012). 
However, since synapsin 1 promoter is present in all neurons, it remains to be determined 
which specific neuronal cell type play underlies the development of the peripheral 
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neuropathy, and whether KCC3 in Schwann cells are also involved in the ontogeny of the 
disease. 
In the present study, we created several novel mouse models to target deletion of KCC3 
in specific cell types by using specific transgenic CRE lines. CRE recombinase is an 
enzyme derived from the P1 Bacteriophage which catalyzes the specific recombination 
between two 34 bp DNA recognition sites (loxP sites). The artificial loxP sites are 
introduced in the target gene, Slc12a6 in this case, and a mutant mouse is produced. The 
recombinase which is under a tissue-specific promoter is expressed from DNA (transgene) 
inserted in the genome of a separate mouse. The Sc12a6 gene with loxP sites flanking an 
exon of interest and the recombinase transgene are brought together by crossing the two 
lines of mice. Deletion of KCC3 in small sensory neurons, driven by the Nav1.8 Na
+
 
channel promoter, resulted in mice that exhibited no motor coordination phenotype. In 
contrast, deletion of KCC3 in larger type-Ia proprioceptive afferent neurons driven by 
parvalbumin resulted in a significant loss of locomotion. In these mice, there was also 
trend towards a hyperactivity phenotype. Surprisingly, deletion of KCC3 driven by 
enolase-2, which is supposedly expressed in most mature neurons, failed to recapitulate 
this phenotype. The KCC3 deletion in the Schwann cells driven by desert hedgehog also 
failed to induce a locomotor phenotype. Histology analysis showed that parvalbumin 
positive neurons and enolase2 positive neurons in dorsal root ganglion had different 
expression profiles, consistent with the distinct performances in locomotor tests. Finally, 
histological analysis revealed a significant pathology associated with cells that were 
immunoreactive to parvalbumin. Therefore, our study demonstrates that parvalbumin 
positive neurons played a key role in producing the ACCPN-like locomotor phenotype. 
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2. Methods 
Generation of tissue-specific KCC3 knockout mice. All procedures performed with 
mice were approved by the Vanderbilt University Institutional Animal Care and Use 
Committee. We disrupted the mouse Slc12a6 gene by inserting loxP sites around exon 7 
(131 bp), followed by a neomycin resistance gene cassette flanked by Frt sites. The 
targeting vector was constructed using recombineering techniques to drop the short 5’ 
end and long 3’ end arms of recombination from BAC clone bMQ-302F12 (Geneservice 
Ltd, Cambridge, UK) into a vector containing 3 loxP sites, 2 Frt sites, and a PGK-driven 
neomycin resistance gene cassette. Briefly, a 2526 bp fragment (short arm) was dropped 
from the BAC clone between unique sites located upstream of the first loxP site. A small 
PCR fragment consisting of exon 7 surrounded by short intronic sequences was then 
ligated downstream of the first loxP site. In a final step, larger 7.5 kb fragment (large arm) 
was dropped from the BAC clone downstream of the last loxP site. The construct, 
verified by map digest and partial sequencing, was linearized using NotI. To target the 
gene for homologous recombination, TL-1 ES cells were electroporated with the 
linearized construct and grown on fibroblast feeder cells in Dulbecco’s Modified Eagle 
Medium (D-MEM) medium supplemented with 15% fetal bovine serum, 50 mg/ml 
gentamicin, 1000U/ml LIF, 90 mM β-mercaptoethanol, and 0.2 mg/ml G418. Three 
hundred and fifty independent neomycin-resistant colonies were picked and grown in 96-
well plates on feeder layer, expanded, and analyzed for the presence of the mutant gene 
by performing Southern blot analysis using genomic DNA digested with SphI and 
hybridized with a 
32
P-labeled probe consisting of 347 bp upstream of the left arm of 
recombination. Eight positive clones were identified and one clone (5B1) was injected 
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into C57BL/6J blastocysts. Two chimeric males (> 90% brown fur) were mated with 
C57BL/6J females and germline transmission was obtained. Since these mice carried one 
allele containing the neomycin-resistance gene cassette (3 loxP), they were mated with 
FLPeR mice (obtained from Susan Dymicki, Harvard and backcrossed in our laboratory 
for > 10 generations in C57BL/6J background) to eliminate the neomycin-resistance gene 
cassette. 
Heterozygous KCC3flox mice were first crossed to obtain viable homozygous mice. The 
mice were genotyped using oligonucleotide primers flanking the loxP site located 
upstream of exon 7: forward primer: 5’ TGTGACAGACACTTCCTACAAGCC 3’ and 
reverse primer: 5’ TCAGACTTTGGGAAATTGAACGTAAC 3’. The PCR 
amplification was done using an annealing temperature of 60
o
C and yielded a 294 bp 
fragment from the mutant allele and a smaller 254 bp fragment from the wild-type allele. 
The mice were then crossed with the different transgenic CRE mice to obtain in a first 
step mice carrying the CRE transgenes with one copy of the KCC3floxed allele and in a 
second step mice carrying or not the CRE transgenes with two copies of the KCC3floxed 
allele, i.e. tissue-specific KCC3 knockout mice. Behavioral tests were performed with 
age of mice ranging from 90 – 130 days. 
Accelerated Rotarod. The accelerated rotarod test was performed as previously 
described (Geng et al., 20010). Briefly, neuromotor coordination task was performed 
using an accelerating rotating cylinder (model 47600: Ugo Basile, S.R. Biological 
Research Apparatus, Comerio, Italy). The cylinder was 3 cm in diameter and was covered 
with scored plastic. Mice were confined to a 4 cm long section of the cylinder by gray 
Plexiglas dividers. Three to five mice were placed on the cylinder at once. The rotation 
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rate of the cylinder increased over a 5 min period from 4 to 40 rpm. The latency of each 
mouse to fall off the rotating cylinder was automatically recorded by the device. Mice 
that remained on the rotarod during the 300 s trial period were removed and given a score 
of 300 s. The test was performed for three trials a day for 3 consecutive days. 
Open field. This test was also executed as described earlier (Geng et al., 2010). 
Exploratory and locomotor activities were tested using an open-field activity chamber 
surrounded by a Plexglas enclosure within sound-attenuating cubicles (ENV-022MD-027; 
Med Associates, Inc., St. Albans, VT). The mice were placed in the center of the open 
field and their activity was monitored for 60 min. The test was performed at ambient 
room temperature (25
o
C), moderate light (60 lx), and background noise (80 dB). Distance 
traveled and time spend in the periphery (thigmotaxis) of the chamber were quantified by 
the number of beam crossings. 
Hot-plate assay in Nav1.8-CRE x KCC3
f/f
 mice. The hotplate assay was performed by 
placing the mice individually on a platform maintained at 52°C to 55°C (Hot-Plate 
Analgesia Meter; Columbus Instruments, Columbus, OH). A plastic cylinder measuring 
15 cm (diameter) and 20 cm (height) confined the mouse to the surface of the hotplate. 
The time necessary for the mouse to respond to the thermal stimulus (hindpaw fluttering, 
licking, or withdrawal) was measured using a stopwatch. After the initial response or the 
maximal cutoff time of 15 seconds, the mouse was removed from the hotplate and 
returned to its home cage. A minimal recovery period of 1 day was implemented between 
assays at the two temperatures. 
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Dorsal root ganglia fixation and immunofluorescence staining. Dorsal root ganglia 
were dissected from the lower thoracic to mid-lumbar regions of the vertebral column 
and were placed in a 4% (w/v) solution of PFA (Sigma Aldrich) in 0.1 M PBS (4
o
C, pH 
7.4) overnight. Following fixation, DRG neurons were transferred to a 30% (w/v) sucrose 
solution in 0.1 M PBS for 24 hours ~48 hours before embedding into O.C.T. compound 
(Sakura Tissue-Tek, Thermo Fisher Scientific) blocks. The O.C.T. blocks were stored at 
−20°C before being transferred for cryostat sectioning. Sections were cut 10 μm thick in 
the cryostat microtome at −20°C and were immediately transferred to a room temperature 
microscope slide by gentle touching. The slides were stored at −20°C for further 
histology study. Routine H&E staining was performed for general histology. For 
immunostaining, the slides were defrosted at room temperature for 10 min., and then 
permeabilized with 0.1% Triton X-100 for 5 min. After 2 washes in PBS for 5 min. each, 
the slides were blocked for 30 min with 1% BSA + 1% goat serum in PBS. Primary 
antibodies (anti-PDI antibody (Abcam, Ab27043 1:200), anti-NSE antibody (Abcam, 
ab53025, 1:250), anti-parvalbumin antibody (Abcam, MAB1572, 1:500), anti-Cre 
antibody (Abcam, ab24607, 1:500)) were applied in 1%BSA with PBS at 4°C, overnight. 
On the second day, the slides were washed twice separately with high salt PBS and 
regular PBS, then blocked with 1% BSA + 4% goat serum in PBS for 30 min. Secondary 
antibodies (100 ul, Cy3 conjugated anti-rabbit antibody (1:1000, Jackson 
Immunochemicals) or Alexa Fluor anti-mouse IgG (H+L) (1:400, Invitrogen) were then 
applied and incubated for 60 min at room temperature. After final washes with high salt 
PBS and regular PBS, coverslips were mounted on slides using VectaShield (Vector 
78 
 
Laboratories, Burlingame, CA) and sealed with nail polish. Fluorescence signal was 
visualized using a Carl Zeiss LMS 510 META confocal microscope. 
Spinal cord fixation and immunohistochemistry. Mice were euthanized and lumbar 
vertebra were collected and submerged in 10% neutral buffered formalin for overnight 
fixation.  Following overnight fixation, vertebrae were decalcified in 23% formic acid for 
48 hours.  The vertebrae were cut in cross sections, placed in tissue cassettes, processed 
with hematoxylin and eosin for identification of dorsal root ganglia. Once the sections 
containing DRGs were identified, unstained slides were cut for immunohistochemical 
labeling with anti-mouse parvalbumin (Cat# p3088, Sigma) at a 1:200 dilution on a Bond 
Max Autostainer (Leica), using EDTA antigen retrieval for 20 minutes, and 
Ultravision
TM
 Quanto Mouse-on-mouse blocking kit (Thermo Fisher Scientific).  
Western blot analysis. After euthanasia, brains from Eno2-CRE x KCC3
f/f
 and KCC3
f/f
 
control mice were promptly removed and flash frozen in liquid Nitrogen. Tissue was then 
homogenized using a dounce/Teflon pestle in 0.32M sucrose buffer (0.32 M sucrose, 5 
mM Tris-Cl pH 7.5, 2 mM EDTA, 2.5 mM β-mercaptoethanol and protease inhibitors), 
spun at 4,000 rpm for 10 min, followed by 9,000 rpm for 20 min, and 100,000 rpm for 1 
hour. Pellets (microsomal fractions) were resuspended in sucrose buffer and the protein 
concentration was measured using standard Bradford Assay. Equal amount of protein 
(200 ug) was loaded on a 9% SDS-polyacrylamide gel, separated, and electrotransferred 
onto  (ThermoFisher Scientific). The 
membrane was incubated for 2 h at room temperature in blocking solution (5% nonfat 
milk in TBST, i.e. 150 mM NaCl, 10 mM Tris, 0.5% Tween 20), and incubated with 
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rabbit polyclonal anti-KCC3 antibody (1:1000) overnight at 4
o
C. The membrane was the 
thoroughly washed in TBST, incubated with horseradish peroxidase-conjugated 
secondary antibody in blocking solution (1:5000) for 1 hour at RT, and washed again for 
2 h in TBST. Protein bands were visualized by chemiluminescence (ECL Plus, 
Amersham Biosciences, Piscataway, NJ). 
Statistical analysis. For rotarod experiment, statistical analyses were performed using 
SAS software (version 9.3, SAS Institute, Inc., Cary, NC). To account for the effects of 
animal group, days, and trials on rotorod times, a three-way repeated measures ANOVA 
test was utilized. The error terms of the different animal groups was modeled as 
independent variables while both the error terms of days and trials were correlated 
variables. Numerous covariate matrices were used to model both days and trials with the 
matrix that best fit the data ultimately being used (autoregressive model of order 1). To 
analyze the trends of rotorod times based on days and trials, Bonferroni-corrected linear 
and quadratic contrasts were constructed for both of these variables. P < 0.05 was 
considered statistically significant.  For other analyses, two-tailed paired t-tests were 
performed using GraphPad Prism (version 3.0, GraphPad Sotwares, Inc., La Jolla, CA). 
Data were noted to be significant at P < 0.05 and highly significant at P < 0.001. 
 
3. Results  
In order to determine the cellular origin of HSMN/ACC, we created several conditional 
KCC3 knockout mouse lines by using Cre mediated recombination under the control of 
tissue-specific promoters. First we created a mouse in which the KCC3 was flanked by 
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loxP sites. A construct targeting exon 7 was engineered (Figure 22) and electroporated in 
mouse embryonic stem cells. After germline transmission and elimination of the 
neomycin-resistance gene cassette, a 3 kb fragment was PCR amplified to demonstrate 
recombination in the proper locus. Sequencing of the fragment revealed correct 5’ 
sequence and presence of the exon and of loxP sites at the 3’ end, demonstrating 
recombination in the proper KCC3 locus.  
As previous report has shown that KCC3 KO mice display severe motor and locomotor 
abnormalities (Boettger et al., 2003; Howard et al., 2002), we subjected all our 
conditional KCC3 knockout mice to a standard protocol of accelerating rotarod: 3 trials a 
day for 3 days. The test assesses fore- and hindlimb balance coordination as well as a 
learning component for this motor task (Karl et al., 2003). Locomotor activity was also 
assessed in an open-field chamber equipped with infrared beams. Each mouse was 
separately monitored for distance traveled during a specific time period. For our first 
tissue-specific knockout mouse line, we crossed KCC3
flox/flox
 mice with animals that 
express the Cre recombinase under the Nav1.8 promoter (Stirling et al., 2005). Nav 1.8 is 
a voltage-gated sodium channel which is expressed in a subset of sensory neurons, 85% 
or more of which are nociceptors. Thus, we generated a mouse where KCC3 deletion is 
targeted in nociceptive neurons. As shown in Figure 23, we observed no difference 
between wild-type and Nav1.8-driven KCC3 knockout mice (F(1, 15) = 2.76; P = 0.1173, 
8-9 mice per group). When we performed statistical analysis of trials or days, we 
observed a very significant difference: F(6, 90) = 4.4, P = 0.0006 for trials and F(2, 30) = 7.88, 
P = 0.0018 for days, indicating that the mice are learning the task or performing better 
with each trial and each day of trials. The relationship between trials was linear: F(2, 90) = 
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5.84, P = 0.002, instead of quadratic: F(1,90) = 0.57, P = 0.05778. There was also no 
difference in total distance travelled in the open field test, as the two tailed t-test 
demonstrated a P value of 0.3696 (t = 0.9270, df = 14, n = 8-9 mice per group). As 
Nav1.8 is expressed in nociceptive neurons, we also tested the mice for a nociception 
phenotype. There was no statistical differences between the two groups of mice in the 
response latency (withdrawal times) to heat-evoked nociceptive stimuli at 52
o
C (t = 
0.8307, df = 15, P = 0.4192), or 55
o
C (t = 0.6465, df = 15, P = 0.5277). 
To explore the possibility that the locomotor deficit is caused by KCC3 deletion in 
Schwann cells, we utilized a transgenic mouse expressing the CRE recombinase under 
the desert hedgehog (Dhh) promoter, desert hedgehog being a protein expressed 
exclusively in Schwann cells (Parmantier et al., 1999) and Sertoli cells in testis (Bitgood 
et al., 1996). Figure 24 presents the data of the accelerated rotorod and open field tests 
performed in control (KCC3
f/f
) and Schwann cell knockout (Dhh-CRE x KCC3
f/f
) sibling 
mice. No differences were observed between genotypes in the rotorod test (F(1, 14) = 0; P 
= 0.9741, 8 mice per group). Again, all mice learned the task as the differences between 
trials and days were highly significant: F(6, 84) = 4.82, P = 0.0003 and F(2, 28) = 18.99, P 
< 0.,0001), respectively. Similarly, we observed no phenotype in the open field test (t = 
0.2828, df = 15, P = 0.7812). 
To confirm that neurons were involved in the development of the phenotype, we used 
enolase-2-CRE (Eno2-CRE) mice to drive deletion of KCC3 in neurons. Surprisingly, we 
observed no locomotor deficit in these mice (Figure 25).There was no difference between 
genotypes in the latency to fall the accelerating rod: F(1,10) = 3.37, P = 0.0962 nor in the 
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Figure 22. Generation of the KCC3
flox/flox
 mouse. 
 
A. Schematic representation of the Slc12a6 (KCC3) gene around exon 5-11. Highlighted are two 
SphI restriction sites separated by 8 kb genomic sequence. Location of a 347 bp PCR 
fragment/
32
P-labelled probe (red box) is also indicated. B. Construct containing a 2950 bp 
genomic DNA sequence representing the 5’ arm of recombination (short black box), loxP sites 
flanking exon 7, followed by a PGK-driven neomycin resistance gene cassette flanked by FRT 
sites, and a 7500 bp 3’ arm of recombination (long black box). A SphI site was inserted 
downstream of exon 7, reducing the size of the SphI fragment recognized by the 5’ probe from 8 
to 4 kb. C. Portion of the ES cell screening Southern blot (SphI digest) showing 13 clones with 8 
kb genomic fragment (wild-type allele),  including 2 clones with an additional 4 kb fragment 
(mutant allele). D. Genotyping of 2 litters of pups from heterozygous breeding showing PCR 
fragments from wild-type and mutant alleles. 
 
83 
 
ability to learn the task, as there was highly significant difference between trials (F(6, 60) = 
8.44, P < 0.0001) or days (F(2, 20) = 8.38, P = 0.0023). There was also no difference in the 
distance traveled in the open-field test (two-tailed t test with t = 0.03740, df = 10, P = 
0.9709). To determine the extent of KCC3 deletion in central neurons, we performed a 
Western blot analysis of KCC3 from brains obtained from control (KCC3
f/f
) and tissue-
specific knockout (Eno2-CRE x KCC3
f/f
) mice. As seen in the inset of Figure 25, there 
was significant decrease in KCC3 expression in the brain of Eno2-CRE x KCC3
f/f
 mice, 
indicating that this promoter efficiently drove deletion of the cotransporter in neuronal 
populations in the brain. Expression of the CRE recombinase in sensory DRG neurons 
was examined by immunofluorescence in a later Figure. 
Next, we targeted deletion of KCC3 in proprioceptive neurons (Arber et al., 2000) by 
using a parvalbumin-CRE (Prvlb-CRE) transgenic mouse (Hippenmeyer et al., 2005). 
When locomotion and balance coordination was measured in Prvlb-CRE x KCC3
f/f
 mice 
compared to their control littermate, we observed a phenotype with knockout mice falling 
significantly faster: < 150 sec versus >250 sec: F(1,17) = 42, P < 0.0001(Figure 26). The 
knockout mice, however, were able to improve their performance as the difference 
between trials was highly significant (F(6,102) = 10.38, P < 0.0001), as was the difference 
between days (F(2,34) = 20.76, P < 0.001).  The differences in the average rotorod times 
between the two animal groups were similar for each of the three days (F(2,34) = 3.04, P = 
0.0592) and each of the three trials within each day (F(6,102) = 1.89, P = 0.0897), indicating 
absence of group day interaction or group trial interaction. When the locomotor activity was 
assessed through the open field, we observed a trend towards hyperactivity, although it did 
not reach statistical significance. 
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B. 
Figure 23. Absence of locomotor phenotype in Nav1.8-driven KCC3 knockout mice.  
 
A. Accelerated rotorod test (4 to 40 rpm, 5 min) performed in control (KCC3
f/f
) and tissue-
specific knockout (Nav1.8-CRE x KCC3
f/f
) mice. Test was given three times a day for 3 
consecutive days. The latency to fall from the rotating rod to the platform was measured in 
seconds. B. Locomotor activity as measured by the distance traveled (cm) in the open filed 
chamber over a period of 60 min. Statistical analyses showed no significant differences 
between groups (see text). N = 8-9 mice per group. 
 
85 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Absence of locomotor phenotype in Dhh-driven KCC3 knockout mice.  
 
A. Accelerated rotorod test (4 to 40 rpm, 5 min) performed in control (KCC3
f/f
) and tissue-
specific knockout (Dhh-CRE x KCC3
f/f
) mice. Test was given three times a day for 3 
consecutive days. The latency to fall from the rotating rod to the platform was measured in 
seconds. B. Locomotor activity as measured by the distance traveled (cm) in the open filed 
chamber over a period of 60 min. Statistical analyses showed no significant differences 
between groups (see text). N = 10 mice per group. 
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Figure 25. Absence of locomotor phenotype in Eno2-driven KCC3 knockout mice.   
 
A. Accelerated rotorod test (4 to 40 rpm, 5 min) performed in control (KCC3
f/f
) and tissue-
specific knockout (Eno2-CRE x KCC3
f/f
) mice. Test was given three times a day for 3 
consecutive days. The latency to fall from the rotating rod to the platform was measured in 
seconds. Inset: Western blot analysis of KCC3 expression in brain of 3 controls and 3 Eno2-CRE 
driven knockout mice. B. Locomotor activity as measured by the distance traveled (cm) in the 
open filed chamber over a period of 60 min. Statistical analyses showed no significant differences 
between groups (see text). N = 6 mice per group. 
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Using immunofluorescence, we examined the expression of parvalbumin and enolase-2 
in isolated dorsal root ganglion from wild-type mice, and expression of CRE in DRGs 
isolated from Prvlb-CRE x KCC3
f/f
 and Eno2-CRE x KCC3
f/f
 mice. As described in the 
method section, the ganglia were promptly removed from the spinal cord, fixed, 
cryoprotected, embedded, and cryosectioned. As seen in Figure 27A, strong parvalbumin 
staining was observed in a subset of large cells, whereas other cells showed weak or no 
staining. In contrast, enolase staining was punctated in dorsal root ganglia (Fig. 27B), 
demonstrating a very different pattern of expression (merge, Fig. 27C). Consistent with 
this staining pattern in wild-type mice, CRE expression was observed in large neurons in 
the Prvlb-CRE mouse, while punctated staining was observed in the Eno2-CRE mouse. 
Further analyses of dorsal root ganglia were performed by immunocytochemistry. Entire 
spinal cord sections were H&E stained and when dorsal root ganglia were observed, the 
next contiguous section was stained with anti-parvalbumin antibody. Large vacuoles, 
reminiscent of what was observed in brain and spinal cord in the global KCC3 knockout 
(Boettger et al., 2003), were observed in dorsal roots of Prvlb-CRE x KCC3 knockout 
mice (Figure 28, arrows). In addition, many structures containing dense material (arrow 
heads) were also observed in the DRG of these mice. The vacuoles and structures were 
immuno-reactive with the anti-parvalbumin antibody (Figure 28C, 28D). To better 
understand the histopathlogy of the dorsal root ganglia in these tissue-specific knockout 
mice, we isolated spinal cords from wild-type mice and KCC3 global knockout mice. The 
tissues were subjected to the exact same protocol, from animal perfusion to parvalbumin 
antibody detection. While no vacuoles or dense materials were observed in DRGs from 
wild-type mice (Figure 29A, B), pathology similar to that observed in parvalbumin- 
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Figure 26. A locomotor phenotype is observed in parvalbumin-driven KCC3 knockout mice.  
 
A. Accelerated rotorod test (4 to 40 rpm, 5 min) performed in control (KCC3
f/f
) and tissue-
specific knockout (Eno2-CRE x KCC3
f/f
) mice. Test was given three times a day for 3 
consecutive days. The latency to fall from the rotating rod to the platform was measured in 
seconds. B. Locomotor activity as measured by the distance traveled (cm) in the open filed 
chamber over a period of 60 min. Statistical analyses showed highly significant difference 
between groups in the rotorod test (see text), but no difference in the activity/open field test. N = 
8-11 mice per group. *** P < 0.001, highly significant. 
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driven KCC3 knockout was also observed in the DRGs of global knockout mice (Figure 
29C, D). 
 
4. Discussion  
To address the cellular origin of the locomotor deficit associated with the disruption of 
KCC3 in mice and the development of the early onset peripheral neuropathy disorder 
observed in HSN/ACC patients (Boettger et al., 2003; Howard et al., 2002), we created 
several tissue-specific knockout lines. Only when KCC3 was targeted in parvalbumin 
positive neurons did we detect a locomotor deficit similar to the one observed in the 
global knockout animals. Parvalbumin is a member of a large family of EF-hand 
containing calcium-binding proteins, which contains in excess of 200 members in human 
(Popelár et al., 2013). It is essential for Ca
2+ 
homeostasis and the modulation of 
intracellular Ca
2+ 
concentration in specific populations of neurons (Celio, 1990). In the 
brain, parvalbumin is almost exclusively expressed in subpopulations of inhibitory fast-
spiking GABAergic interneurons located in many different brain regions such as cortex, 
cerebellum, hippocampus and the reticular nucleus of the thalamus (Celio, 1990; Münkle 
et al., 2000; Ohshima et al., 1991). Deficits in parvalbumin expressing interneurons have 
been linked to cognitive impairments in animal models of Alzheimer disease (Verret et 
al., 2012). In the peripheral nervous system, parvalbumin is expressed in proprioceptive 
type Ia fibers (Figure 30). The locomotor deficit observed in the Prvlb-CRE x KCC3
f/f
 
mice is unlikely related to a disruption of parvalbumin in these mice. Indeed, the 
transgenic mouse was created by inserting the CRE recombinase in the parvalbumin gene 
locus using an internal ribosomal entry site (IRES) at the end of the exons encoding the 
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Figure 27. Parvalbumin and enolase 2 were expressed in different structures of DRG 
neurons. 
 
A-C. Longitudinal sections of DRG neurons from wild-type (n=3) mice were analyzed using 
immunofluorescence antibody against parvalbumin (A, green) and enolase 2 (B, red). Panel C 
represents the summation of both signals. D-E. Longitudinal sections of DRG neurons from 
parvalbumin-CRE x KCC3
f/f
 mice and Eno2-CRE x KCC3
f/f
 mice were immunostained with CRE 
antibody. CRE expression was observed in both mice and mirrored the signal seen with the two 
protein-specific antibodies. 
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Figure 28. Histological analysis of dorsal root ganglia in Prvlb-CRE x KCC3f/f mice.   
 
A. Partial view of spinal cord with dorsal root with H&E stain at a magnification of 10x. B. 
Higher magnification (40x) of the dorsal root of Panel A. C. Contiguous section showing spinal 
cord stained with anti-parvalbumin antibody. D. Higher magnification (40x) of the dorsal root 
showing parvalbumin staining of structures surrounding vacuoles (arrows) as well as some dense 
material which is parvalbumin immunoreactive. The following structures are labeled: s.c. = spinal 
cord; m. = muscle; bn. = bone, dashed circle = dorsal root ganglion.  
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Figure 29. Histological analysis of dorsal root ganglia from wild-type and global KCC3 
knockout mice.  
 
A. Partial view of spinal cord with dorsal root and parvalbumin staining in wild-type mouse at a 
magnification of 10x. B. Higher magnification (40x) of the dorsal root of Panel A, showing 
absence of pathology. C. Partial view of spinal cord with dorsal root and parvalbumin staining in 
global KCC3 knockout mouse at a magnification of 10x. D. Higher magnification (40x) of the 
dorsal root of Panel C, showing pathology similar to that observed in Figure 7. The following 
structures are labeled: s.c. = spinal cord; m. = muscle; bn. = bone, dashed circle = dorsal root 
ganglion, p = positive neuron, n = negative neuron.  
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Figure 30. Schematic representation of parvalbumin expression in neurons.   
 
In brain, parvalbumin is expressed in fast-spiking GABAergic interneurons (PV) which provide 
inhibitory input to pyramidal neurons (P). Another type of interneuron is depicted green. In the 
periphery, parvalbumin is expressed in type Ia large diameter proprioceptive afferents neurons 
which project to both middle spinal cord interneurons and to ventral motor neurons. 
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calcium binding protein. Thus, both parvalbumin and CRE transcripts are expressed 
under the parvalbumin promoter. Parvalbumin expression was verified by our 
immunocytochemistry studies of dorsal root ganglia which showed parvalbumin 
expression in the tissue-specific knockout mice (Figures 28). Furthermore, it was shown 
that disruption of parvalbumin in mice had no phenotype in the rotarod assay (Farré-
Castany et al., 2007). Therefore, the observed phenotype likely originates from disruption 
of KCC3 in proprioceptive DRG neurons. In fact, we demonstrated that the abnormal 
structures in the dorsal root ganglia of either tissue-specific or global KCC3 knockout, i.e. 
vacuoles and dense material, had parvalbumin immunoreactivity (Figures 28 and 29). 
Thus, the pathology clearly involves parvalbumin fibers. This observation makes the 
involvement of CNS interneurons (e.g. in cerebellum) in the locomotor phenotype less 
likely.  On the other hand, decreased KCC3 expression in CNS interneurons might 
explain the hyperactivity observed in the neuronal-specific KCC3 knockout mouse 
(Shekarabi et al., 2012), and the hyperactivity trend observed in our parvalbumin-driven 
KCC3 knockout mouse. Decreased activity of parvalbumin-positive interneurons would 
result in an increased excitatory network drive, leading to hyperactivity. Interestingly, 
network hyperexcitability and increased susceptibility to epileptic seizures were also 
demonstrated in parvalbumin null mice (Schwaller et al., 2004). Although not tested in 
this study, global KCC3 knockout mice also demonstrate a reduced threshold to develop 
seizures (Boettger et al., 2003). 
None of the other 3 tissue specific knockout mice showed the same locomotor deficit as 
the Parvlb-CRE x KCC3
f/f
 mice. Because global KCC3 knockout mice demonstrated 
hypomyelination and periaxonal swelling (Byun and Delpire, 2007), we postulated that 
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Schwann cells might contribute to the phenotype, and more specifically KCC3 as a 
mechanism which drive salts and water out of the cell might be involved in the process of 
myelin compaction. We therefore targeted KCC3 in Schwann cells by crossing our floxed 
mouse with Desert hedgehog (Dhh)-driven CRE mice. These mice have been used to 
successfully delete Pten in Schwann cells (Keng et al., 2012). Dhh is a member of the 
Hedgehogs family of intercellular signaling proteins that are best known for controlling 
tissue patterning during development (Ferent and Traiffort, 2014). Dhh is specifically 
expressed in Schwann cells of the nervous system and Sertoli cells in the testis in 
mammals. Mutations in human DHH have been identified resulting in gonade dysgenesis 
associated with polyneuropathy (Umehara et al., 2000). In addition, Dhh knockout (KO) 
mice have abnormal perineurial sheath formation, suggesting a key role of controlling the 
connective tissue sheaths formation around peripheral nerves (Bitgood et al., 1996; 
Parmantier et al., 1999). Our results showed no locomotor phenotype in these mice, 
indicating no participation of Schwann cell KCC3 in the development of ACCPN. Note 
that this observation does not rule out the participation of Schwann cells themselves in 
ACCPN, as these cells clearly interact with both normal and degenerating neurons in the 
nerves of KCC3 knockout mice or ACCPN patients. The lack of phenotype also indicates 
that the Schwann cell deficit observed in the global KCC3 knockout and in patients is 
likely to be secondary to the neuronal degeneration(Byun and Delpire, 2007; Larbrisseau 
et al., 1984). 
To test whether the locomotor and balance deficit is related to an inability to sense 
mechanical pressure, we crossed the KCC3
f/f
 line with Nav1.8-driven CRE mice (Stirling 
et al., 2005). Indeed, Nav1.8 is a voltage-gated sodium channel alpha subunit which is 
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found within small-diameter sensory DRG neurons and is involved in temperature and 
mechanical pressure perception as well as nociception (Liu and Wood, 2011). As no 
locomotor deficit was observed in these mice, we can conclude that the accelerated 
rotarod phenotype observed in the global KCC3 knockout mice is not related to a role of 
the cotransporter in these small sensory fibers. As we had the Nav1.8-CRE x KCC3f/f 
mouse line, we also tested the mice for a heat-evoked nociception phenotype at two 
noxious temperatures (52
o
C and 55
o
C). There was no difference observed between 
genotypes in the latency to respond to the thermal stimuli. Our data therefore indicate that 
KCC3 is unlikely to play a key role in the physiology of these neurons. 
In our studies, we included a CRE line, Eno2-CRE, that we thought would produce 
knockout of KCC3 in all neurons. This line was our version of the synapsin 1-CRE line 
used by Shekarabi and coworkers (Shekarabi et al., 2012). Neuron specific enolase (Eno2, 
γ-enolase) is a glycolytic enzyme that catalyzes the conversion of phosphoglycerate to 
phosphoenol pyruvate in neurons (Marangos and Schmechel, 1987). Enolase 2 expression 
started shortly after synaptogenesis and is shown to be expressed in most mature neurons 
and neuroendocrine cells, thus making it a useful mature neuron specific marker (Bock 
and Dissing, 1975; Whitehead et al., 1982). We were surprised by the absence of a 
locomotor phenotype in Eno2-CRE x KCC3
f/f
 mice (Figure 25). To generate the 
transgenic Eno2-CRE mice, a 1.8-kb DNA promoter element which is located upstream 
of the rat NSE gene was inserted upstream of the CRE recombinase (Frugier et al., 2000). 
As demonstrated by our Western blot analysis of KCC3 expression, recombination was 
extremely efficient in the brain of Eno2-CRE positive mice. These data suggest that 
expression of the recombinase is optimal in central but not peripheral neurons. This could 
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be due to either poor enolase-2 expression or weak promoter activity of the transgene in 
sensory neurons. Our immunofluorescence data (Figure 27) showed punctated CRE 
expression signal in DRG, different from the large cell bodies staining we observed in 
Parvlb-CRE mice.  
In conclusion, our study establishes a key role for parvalbumin expressing neurons in the 
development of the locomotor phenotype associated with HSN/ACC. The precise 
function of KCC3 in these cells is still unknown. Our study also indicates that the lack of 
function of KCC3 in Schwann cells nor in neurons sensing mechanical signals does not 
contribute to the locomotor phenotype observed in the HSN/ACC disorder. 
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V. Conclusions and future directions 
 
1. Summary of work   
The goal of my work was to understand the underlying pathogenic mechanism of 
HSN/ACC or ACCPN. ACCPN is a devastating disease with progressive neuropathy and 
partial or complete agenesis of corpus callosum. Scientists have spent decades trying to 
uncover the origin of this disease, and have made important steps towards a better 
understanding of this disorder. Today we know that ACCPN is caused by genetic 
mutations in the SLC12A6 gene KCC3, and through a neuron-specific tissue specific 
KCC3 knockout, it has been established that the ACCPN disease is mostly driven by 
neural tissues. However, the current progress or understanding is still far away from 
allowing for the development of therapies for this disease. 
In my study, I first characterized in heterologous expression systems the properties of a 
KCC3 mutation that was found during the cloning of the cDNA encoding the mouse 
KCC3. Compared with other known KCC3 mutations, KCC3-E289G was able to be 
produced as a full-length protein, therefore conserving the C-terminal which was lost in 
most other mutations. Through uptake experiments performed in frog oocytes, we 
demonstrated that KCC3 is functionally silent. Through cell surface expression studies in 
oocytes and immunofluorescence studies in HEK293 cells, we demonstrated that the 
KCC3-E289G mutant protein was not properly trafficked to the plasma membrane. The 
mutant protein was glycosylation-deficient and arrested in the endoplasmic reticulum or 
the early Golgi. Through co-immunoprecipitation experiments, we showed that hetero-
dimers formed between wild-type and mutant KCC3 proteins, and this dimerization was 
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specific for the K-Cl cotransporters, as it was not observed for NKCC1. We demonstrated 
that glutamic acid residue (E289) was essential for proper trafficking and function of the 
K-Cl cotransporters and had potential dominant-negative effects on other K-Cl 
cotransporters in heterologous expressions systems. 
Concurrently, I created a KCC3 knock-in transgenic mouse with this E289G mutation. 
The first line of KCC3E289G mice was embryonic lethal due to unknown reasons, but 
unrelated to the mutant exon. Through the injection of an independent ES cell clone, I 
was able to generate a new line of KCC3E289G knock-in mice, which was fully viable. I 
performed locomotor behavior tests on these mice and was able to observe a significant 
motor deficit reminiscent of the ACCPN phenotype. I went ahead and performed 
immunohistochemistry studies on isolated DRG neurons from these mice. The fact that 
the KCC3 
E289G/-
 double mutation mice did not shown any locomotor deficit was quite 
puzzling, given that the only KCC3 present in this mouse line was the non-functional 
KCC3E289G. More work needs to be done to analyze whether the copy number is a 
potential reason for the distinct phenotypes of KCC3 
E289G/-
 and KCC3 
E289G/E289G
. 
In a separate study, I addressed the origin of the cells responsible for the development of 
ACCPN. I created four lines of tissue-specific KCC3 knockout mice by taking advantage 
of the Cre-Lox technology.  In these conditional lines, KCC3 was deleted by expressing 
Cre in different cell populations through the use of gene specific promoters: Nav1.8, 
parvalbumin, enolase-2, and desert hedgehog. Among the 4 lines of mice, only the 
parvalbumin-driven line showed a significant locomotor deficit, although not as severe as 
the one observed in the global knockout (Figure 32). The fact that enolase-2 driven 
transgenic mouse did not show a phenotype was quite surprising,  as it was widely 
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believed that the enolase-2 Cre mice was able to drive the recombination in most mature 
neurons of mice. Through immunostaining in isolated DRG neurons, I was able to 
confirm that enolase-2 was not present in all DRG neuron populations and it had a 
distinct expression profile than parvalbumin. Furthermore, H&E staining and 
parvalbumin antibody staining were performed on sections of spinal cords isolated from 
parvalbumin-driven KCC3 mice. Vacuolization and cell degeneration similar to the ones 
observed in global KCC3 knockout were observed in DRG of parvalbumin-driven KCC3 
knockout mice, indicating that these specific proprioceptive neurons are responsible for 
HSN/ACC.  
In the meantime, I noticed that the locomotor deficit in the parvalbumin-driven KCC3 
was milder than the KCC3 global knock out, suggesting there might be other key factors 
contributing to the overall pathology of ACCPN. In fact, when we examine the detailed 
pathological analysis of ACCPN disease in patients, a number of tissues and organs are 
affected. Even though the agenesis of corpus callosum phenotype varies in different 
patients, the sporadic oval vacuoles in the white matter are present in brains of all patients, 
revealing neuron degeneration process in the central nervous systems. This phenotype 
was observed in both the global KO and tissue specific KO mouse models.  
Similar to the nerve degeneration and demyelination in peripheral nerves of mouse 
models, severe nerve pathology in the ACCPN patients is also observed. One of the most 
striking phenotype is the presence of massive enlarged axons and significant decrease of 
myelinated fibers in the dorsal root neurons. A moderate axonal loss is also observed, 
suggesting the abnormal neuron degeneration. In 2 patients from Austria,  sensory action 
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potential was absent (Hauser et al., 1993). Since the parvalbumin positive neurons are 
mostly expressed in large diameter myelinated primary afferents, these pathological 
observations from human and mouse models fit rather quite well, confirming a key role 
for the large myelinated primary afferents during the development of ACCPN disease. 
However, autopsy examination on ACCPN patients suggested that motor neurons could 
also be a contributing factor to the disease. The presence of onion bulbs, formed by the 
concentric lamellae of Schwann cells, was very common in nerve roots. Thin myelin 
sheaths were also observed in a large part of neurons. The nerve conduction velocity was 
reduced in motor neuron of 2 patients, consistent with a similar report in mouse models 
(Byun and Delpire, 2007; Hauser et al., 1993). Most of the patients showed severe 
delayed development of motor function by starting to walk very late or being not able to 
walk without help. Detailed examination on patient showed severe muscular hypotonia, 
significant reduction of spontaneous motility and absence of tendon flexes. Profound 
muscular hypertrophy was observed in some patients and the normal muscle structures 
such as sarcomeric architecture and banding were disrupted in many fibers as well. 
These complicated pathological observations from ACCPN patients revealed the 
complexity of the origin and development of this disease, the discovery of the key roles 
of parvalbumin positive neurons is an important step towards a full understand of this 
syndrome has provided some important clinical insights on potential therapeutic methods 
of ACCPN. One of the first studies following this is to evaluate the possibility whether 
the locomotor phenotype caused by parvalbumin specific KCC3 deletion could be 
rescued, either through genetic method or through small molecular activating KCC3. As 
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discussed in the future direction segment, an inducible parvalbumin specific KCC3 
knockout mouse models would be very helpful to explore this further. However, due to 
the significant differences between human being and mouse nervous systems, the 
application of potential effective ACCPN treatment on mouse should be evaluated 
cautiously.  
 
2. Future directions   
Further studies are clearly needed to understand the connection between KCC3 and the 
physiology of parvalbumin-positive nociceptive neurons. A more detailed phenotyping of 
the mice is needed to assess whether other neurological phenotypes are also related to 
parvalbumin positive neurons. Indeed, parvalbumin is also expressed in central 
interneurons which provide inhibitory input to large pyramidal neurons. Thus, the 
increased activity which was demonstrated in a synapsin-1-driven KCC3 knockout 
(Shekarabi et al., 2012), and suggested in our parvalbumin-driven knockout mouse, might 
be related to the function of KCC3 in interneurons. Note that loss of interneurons 
expressing calbindin or parvalbumin results in increased locomotor phenotype (Farre-
Castany et al., 2007; Shekarabi et al., 2012). Similarly, our parvalbumin-driven KCC3 
mice could be tested for prepulse inhibition and susceptibility to develop epileptic 
seizures (Boettger et al., 2003; Howard et al., 2002; Popelar et al., 2013; Schwaller et al., 
2004). It is interesting that that increased activity was not observed in the global KCC3 
knockout mouse (Figure 31B). This might be due to the severity of the locomotor 
phenotype that affects the overall activity of the mice. 
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Figure 31. Locomotor phenotype in KCC3 global knockout mice. 
 
A. Accelerated rotorod test (4 to 40 rpm, 5 min) performed on two days in wild-type (KCC3), 
heterozygous (KCC3 – hetero), and homozygous (KCC3 – homo) mice. The test was given three 
times on the second day. B. Locomotor activity measured as the distance traveled (cm) in an open 
filed chamber over a 20 min period. Statistical analysis was performed using ANOVA and 
showed significant P < 0.05 difference between homozygous and wild-type mice. N = 12-14 mice 
per group. 
 
104 
 
The fact that a subpopulation of neurons is responsible for the phenotype should also help 
us address the role of KCC3 in these cells. Indeed, parvalbumin-CRE tdTomato mice 
could be used to 1) determine if tdTomato is expressed in a subpopulation of DRG 
neurons and 2) isolate and purify that specific population of cells for cell culture and in 
vitro studies.   
The cells could be enriched by Fluorescence Activated Cell Sorting (FCTS) and placed in 
culture. The role of KCC3 modulating the Cl
-
 reversal potential could be measured as 
previously done with NKCC1 in the laboratory (Sung et al., 2000). Imaging and cell 
volume reconstruction could also be measured to assess the cell volume regulation role of 
KCC3 in these cells. Then, parvalbumin-positive cells could be isolated from the KCC3 
knockout mice, hopefully as soon as parvalbumin positive cells are visible in the mouse 
and before the cells start to degenerate. Cell survival could be measured by plating 
identical number of cells in culture and counting them as a function of time (days) in 
culture.  
The studies we presented with our current KCC3 antibodies were not optimal as 
cotransporter expression could not be easily detected in the plasma membrane.  Future 
studies should work at optimizing the conditions for the antibody or at creating additional 
antibodies to detect cell surface expression of KCC3. One possibility would be to 
generate an antibody directed against an external epitope (extracellular loop), which 
could be used to visualize the cotransporter and quantitate cell surface expression, 
without permeabilizing the cells. 
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The appearance and development of HSN/ACC occurs in early childhood and the 
locomotor phenotype is also noticeable in very young mice. Thus, there is likely a 
developmental component to the disease, even if there is a degenerative component. 
Whether the phenotype can be rescued at any point in time by re-expressing KCC3 can 
be tested in mice. The laboratory has created a new genetically modified KCC3 mouse 
model in which exon 7 (including 100-150 bp upstream and downstream sequence) is 
duplicated with a stop codon introduced in the duplicated exon (Figure 32). The 
duplicated exon is also flanked by loxP sites. This mouse will be used in combination 
with an existing parvalbumin-tTA mouse (available at the Jackson laboratories) and a 
phCMV-teto-CRE mouse available in the laboratory to create an inducible ‘rescue’ 
mouse. Before recombination, the mutated exon 7 will produce a transcript that contains 
a premature stop codon. The mouse will therefore be diseased as KCC3 will not be 
expressed. Upon recombination (induced with doxyxcycline or doxycycline withdrawal 
from food), the exon will be excised and full-length KCC3 will be initiated. There is hope 
that by playing with time of induction, one should be able to determine up to what point 
(if any) the rescue of the phenotype is possible. 
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Figure 32. Design of a KCC3 rescue mouse. 
 
Construct of a KCC3 rescue mouse with exon 7 duplicated. Although insertion of the exon places 
the remainder out of frame, the duplicated exon also includes stop codons. The mouse would be 
crossed to two transgenic lines: one carrying tetracycline transactivator gene product under the 
parvalbumin promoter (B), the other carrying the CRE recombinase with a global promoter 
(phCMV) and tetO elements. Doxycycline (provided in the diet) prevents binding of tTA to the 
TetO elements. Upon doxycycline withdrawal, tTA expressed in parvalbumin-positive cells can 
now bind to TetO elements and initiate expression of the recombinase. Upon recombinase 
expression, the mutant exon 7 is excised and a full-length (wild-type) KCC3 protein can be 
expressed. 
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